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On 25 January 2019, the Health Service Executive 
(HSE) and Tusla, the Child and Family Agency jointly 
launched the Hidden Harm strategic statement, 
Seeing through hidden harm to brighter futures1 
and the Hidden Harm practice guide2 in the Plaza 
Hotel in Tallaght, Dublin. A separate information 
leaflet, Opening our eyes to Hidden Harm,3 was 
also published to support frontline staff working 
with children impacted by parental drug or alcohol 
misuse. 
These publications outline how the two State organisations will 
work together to identify and support children who are adversely 
affected by parental substance misuse. Joint training for HSE and 
Tusla staff working in this area is due to be developed in 2019.
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In brief
All policy decisions involve a certain amount 
of anticipation and speculation, informed or 
otherwise. It is useful to know the range of 
possible outcomes so that resources can be 
allocated effectively and preparations made for 
disruptions to established patterns. Policymaking 
in the drugs area is sometimes reactive to changes 
in behaviour in certain populations, some of 
which may be predictable but often appear, at 
least to policymakers, as sudden aberrations from 
the expected norm. 
A recent initiative1 from the Directorate-General for Justice 
and Consumers at the European Commission provides a 
forum for debate among all stakeholders who can contribute 
to future-oriented policy thinking on substance use. Routine 
monitoring has been the mainstay of evidence-based drug 
policy for two decades. The indicators based on these 
data are now complemented by environmental, cultural, 
and economic information, not just to provide a wider 
perspective but also to find ways to respond more rapidly to 
an ever-changing situation.
The EMCDDA’s trendspotter studies have been designed 
to take advantage of this wider information spectrum, and 
trendspotting methodology is itself a new approach to data 
collection and evidence synthesis. This approach will inform 
policy decisions around the implications for law enforcement 
and health services. By drawing on expertise across a range 
of disciplines, we will be able to refine the tools we use to 
both assess the current situation and observe trends over 
shorter time periods that would not be possible if we relied 
solely on routine monitoring data.
Certain drug use patterns are recognisable across Europe 
but each region, country, and even municipality has its own 
peculiar variation in drug-using behaviour. While increasingly 
sophisticated analytical tools will enable more refined 
and timely pictures of the global situation to be drawn, 
governments charged with implementing strategy need to 
examine how to adapt these tools to the local or national 
situation. Epidemiological analysis and law enforcement 
data have helped us build robust and comparable national 
reports. The very nature of drug-using behaviour means 
that these information sources will only tell us part of the 
story and their capacity to predict future patterns is limited. 
By using other kinds of data and finding ways to integrate 
these into established analytical systems, we will be better 
placed to consider what might happen and more equipped 
to respond to change.
1 The FuturiZe project is a European project to boost knowledge 
exchange and collaboration among the primary stakeholder. 
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The adverse experiences of children living with parents who 
misuse alcohol or other drugs have been termed ‘hidden 
harm’ because these children often remain unknown to 
services. Children living with parents who misuse substances 
are at greater risk of emotional and physical neglect and of 
developing mental health and substance misuse problems later 
in life. Through the National Hidden Harm Project, the HSE and 
Tusla have committed to work together to improve services and 
outcomes for children affected by parental problem alcohol 
and other drug use in Ireland. 
The publications were officially launched by Minister for 
Children and Youth Affairs, Dr Katherine Zappone TD, and 
Minister of State with responsibility for Health Promotion 
and the National Drugs Strategy, Catherine Byrne TD. The 
keynote speech was given by Joy Barlow MBE. Joy Barlow is 
Hidden harm continued an international expert in the field of hidden harm and was a member of the national steering group involved in producing 
the documents launched at the event. Dr Aisling Gillen, service 
director from Tusla, and Joe Doyle, planning specialist from the 
HSE National Social Inclusion Office, also spoke at the launch. 
Claire O’Dwyer
1 HSE and Tusla (2019) Hidden Harm strategic statement: seeing 
through hidden harm to brighter futures. Dublin: HSE and Tusla. 
https://www.drugsandalcohol.ie/30190/2/StrategicGuide.pdf 
2 HSE and Tusla (2019) Hidden Harm practice guide: seeing through 
hidden harm to brighter futures. Dublin: HSE and Tusla.  
https://www.drugsandalcohol.ie/30190/1/PracticeGuide.pdf
3 North South Hidden Harm Group (2019) Opening our eyes to Hidden 
Harm: empowering frontline workers to support children and young 
people affected by parental problem alcohol and other drug use. 
Dublin: HSE and Tusla.     
https://www.drugsandalcohol.ie/30190/3/Leaflet_Jan_16th.pdf 
POLICY AND LEGISLATION 
HRB evidence review 
on dual diagnosis 
treatment service
The Health Research Board (HRB) recently published a review 
entitled Treatment services for people with co-occurring 
substance use and mental health problems: a rapid realist 
synthesis.1 This report is part of the HRB Drug and Alcohol 
Evidence Review series and was undertaken by a team from 
the Georgia Health Policy Center. The three initial research 
questions guiding the review were:
• What interventions improve treatment and personal 
functioning outcomes for people with co-occurring 
substance use and mental health problems and in what 
circumstances do they work?
• What aspects of integrative programmes for the treatment 
of co-occurring substance use and mental health 
problems trigger positive system outcomes and in what 
circumstances do these outcomes occur?
• What existing models of care for adults with co-occurring 
substance use and mental health problems lead to positive 
treatment outcomes and successful service integration?
A number of systematic reviews have examined interventions 
responding to specific mental health conditions or substances. 
These reviews were limited as they focused on particular 
substances or particular mental health conditions. While the 
evidence suggests that greater integration of mental health 
and addiction services leads to improved treatment outcomes, 
recent studies from the United States suggest that the capacity 
of services to provide an effective response for clients with 
co-occurring problems is very limited. The purpose of the HRB 
realist review was to understand what aspects of the integrative 
process made it more likely that better treatment outcomes 
would be achieved. In other words, how can we get an 
understanding of what works for whom in what circumstances 
so that the integration of services benefits the users of these 
services. 
The HRB asked the review team to take a realist approach 
to studying the literature on the topic. This means that they 
sought to identify the characteristics, or mechanisms, that are 
more likely to result in successful implementation of evidence-
based treatments and the contexts in which this change 
occurs. An important aspect of the realist approach is to 
understand the context in which service providers and others 
will benefit from the knowledge contained in the review. The 
review team met with a number of knowledge users at an early 
point in the review process and, based on a thematic analysis 
of the discussions at these meetings, it generated 10 theory 
statements to guide the literature search, data extraction, 
and analysis (see Table 1). This theory-driven approach is an 
essential part of the realist synthesis process.
The literature search involved two stages, the first 
concentrating on studies on mental health and substance use 
treatment, integration of health programmes and services, 
and articles on integrated dual diagnosis models of care. The 
second stage broadened the search and looked for studies 
relevant to the topics of peer support, inclusion in service and 
care decisions, and recognition of the value of lived experience. 
The review team synthesised the data from the selected 
articles and aligned the context, mechanism, and outcomes 
found in the literature with each research question. 
The 10 theory statements were grouped into outcome areas 
of integration, access, and individual and family treatment 
outcomes, and the findings of the review are presented by 
these outcome areas. 
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Table 2: Four-level framework providing a structure to organise potential action
Level Potential action
Policy/System • Create incentives in payment to providers for integrating care of individuals with co-occurring 
diagnosis
• When developing service payment agreements, include deliverables that recognise the long path to 
recovery
• Analyse the system as it relates to access to psychological services and align providers with service 
needs
• Examine payment structure for peer mentors, coaches, and instructors
• Explore how resources can be allocated to support a holistic approach to care (e.g. housing, 
supportive employment)
Organisation/Provider • Build a knowledgeable, integrated workforce that keeps the individual at the centre
• Develop a common language among different provider types, consumers, and families
• Examine training modes and build in time to support provider training and cross-training to build 
competence and confidence
• Build a culture of hope
Service/Treatment • Create a learning community among the current integrated programmes
• Conduct a realist evaluation of the current work and use the learnings to improve current 
programmes and build others 
• Allocate resources to support the creation of new integration pilot programmes that include 
resources for programmes, technical assistance, and peer support from current integrated 
programmes
• Use the evidence from this review to guide future programme development
Individual/Family • Build systems for co-production at each level of the system: policy, provider, treatment design, and 
individual care
Table 1: Final theory statements for rapid realist synthesis
Number Theory statement
1 Integration of existing services, particularly community-based services, supports access to care and minimises 
barriers faced with creation of new service lines. 
2 Integrated treatment requires training and cross-training of substance use and mental health service providers at 
multiple levels.
3 Improved coordination between providers (substance use, mental health, and primary care) will break down 
administrative silos and improve access to timely diagnosis, care, and treatment.
4 Services must be tailored to the local context and the individual’s needs and circumstances to be most effective.
5 Including service users and families in service and care decisions results in better outcomes for individuals and their 
families.
6 A knowledge of local efforts already in place and co-production with service providers and individuals with lived 
experience is needed to develop practice-informed strategies and policies that take known facilitators and 
implementation challenges into consideration.
7 Resources (financial and otherwise) must accompany strategy and policy to enable integration and improve service 
delivery and individual outcomes.
8 When treatment takes a holistic view and includes housing and social supports, individual outcomes are improved.
9 A holistic model to mental health is needed to improve mental health outcomes, particularly among individuals with 
co-occurring mental health and substance use disorders.
10 Peer support facilitates recovery and positive outcomes for individuals with co-occurring mental health and 
substance use disorders.
Evidence review on dual 
diagnosis treatment service continued
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integrated system. Local integrated programmes provide a 
starting place for learning and integrating knowledge about 
treatment and building a culture of co-production that 
supports putting the individual at the centre of the system. 
The four-level framework that emerged from this project 
provides a structure to organise potential steps (see Table 2). 
At the policy/system level, high-leverage steps may focus on 
the alignment of resources. At the organisation/provider level, 
a focus on building a knowledgeable workforce is important. 
Initial recommendations, included in the table for each level, 
are focused on a few preliminary actions that may have high 
leverage and build on what currently exists. A next useful step 
could be a collaborative session with local Irish knowledge 
users to meaningfully mine the findings for appropriate 
actions and would be in keeping with the co-production 
recommendation. 
Conclusion
The realist review and synthesis begins to answer the 
overarching question of how can integration using effective 
models of care improve outcomes for individuals with 
co-occurring mental health and substance use disorders.  
Integration is not a single concept related to a specific 
treatment or relationship among providers, but rather a 
complex, multifaceted portfolio of interrelated parts of a 
system. Central to the development of integrated models is a 
four-level framework for integration that is co-produced by 
policymakers, providers, and clients at the policy, organisation 
or provider, treatment, and individual levels. Policies and 
resources need to be aligned to create incentives for providing 
integrated care, while a knowledgeable, coordinated workforce 
keeps the individual at the centre. 
Brian Galvin
1 Minyard K, Manteuffel B, Smith CM, Attell BK, Landers G, Schlanger 
M and Dore E (2019) Treatment services for people with co-
occurring substance use and mental health problems. A rapid 
realist synthesis. HRB Drug and Alcohol Evidence Reviews 6.  Dublin: 
Health Research Board. https://www.drugsandalcohol.ie/30376
Evidence review on dual 
diagnosis treatment service continued
Main findings
Integration
Each of the three outcome areas is associated with a 
different context. The mechanisms in improved integration 
are associated with the provider context. Alignment of 
organisational and financial resources with strategy and policy 
is needed for integration of services but it does not guarantee 
success. A culture of hope and an empowering collaborative 
climate help to build providers’ confidence in their ability to 
implement changes in services and to address the needs of 
those with comorbid problems. Providers’ belief that change 
is possible and enthusiasm for implementing these changes 
serve as catalysts for the change that integrated care requires. 
Staff confidence and hope is also developed when training is 
delivered in an environment that supports co-production and 
values the knowledge of individuals with lived experience. 
When financial resources are applied in an empowering 
collaborative climate, formal partnerships can be developed 
across organisations and an open dialogue supporting 
a common language can develop. In this atmosphere, 
intermediary outcomes, such as unified case management, 
coordination of care, and shared treatment plans, are more 
likely to result and enable better integration of services.
Access
The context in relation to access mechanisms is mental health 
or substance use services undergoing change and seeking 
to work with providers of different kinds of services. In this 
context, staff knowledge and increased confidence related to 
training is associated with prompt diagnosis and consequently 
increased access to treatment. Staff adoption of a client-
centred approach and displays of kindness are associated with 
increased patient engagement.
Individual and family treatment outcomes
The context for this category of outcomes is the care setting. 
A dominant theme under this category is the importance of 
engagement in treatment. Conditions that are associated 
with engagement are a supportive social network, progress 
in self-management behaviours, and stability in basic social 
and employment needs. A care system that works with the 
individual to establish a secure and stable environment makes 
engagement in treatment and recovery more likely.
The literature also reveals three more difficult-to-observe 
mechanisms that are part of this complex system: trust, 
flexibility, and hope. There are specific actions and orientations 
that contribute to trust. For example, creating an environment 
that is intentional about displaying simple acts of kindness will 
help build trust. Purposefully building flexibility into treatment 
through co-design will help build the conditions necessary for 
recovery. Building a culture of hope among providers, family, 
and clients through instilling confidence, self-esteem, and 
empowerment is critical to recovery. 
Initial recommendations 
The findings of this realist review and the wisdom gained 
from local knowledge users provide ideas on how to build an 
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cannabis and 
cannabinoids: Q&A 
for policymaking
The medical use of cannabis and cannabinoids is a complex 
and challenging field. There is a wide range of issues to 
be considered by policymakers and other stakeholders 
when making decisions about the best approach to take. In 
December 2018, the European Monitoring Centre for Drugs 
and Drug Addiction (EMCDDA) published a report on the topic 
to help support this process – Medical use of cannabis and 
cannabinoids: questions and answers for policymaking.1 It is 
supported by a background paper: A summary of reviews of 
evidence on the efficacy and safety of medical use of cannabis 
and cannabinoids.2
The report focuses on four main areas in relation to the 
medical use of cannabis and cannabinoids: a review of the 
evidence for their medical use across a number of conditions; 
the relevant regulatory frameworks; the approaches countries 
have used to allow access to them; and the regulatory 
challenges faced. This is a detailed report and just a selection 
of the key findings is presented below.
In what is a very fast-moving field characterised by an 
often hotly contested debate, this report has sought 
to provide an objective look at current evidence, 
practice and experience. (p. 34)1
Which substances are being discussed?
Broad terms such as ‘medicinal cannabis’ are often used when 
discussing this topic. The report highlights the need to define 
in a clearer way the kinds of substances involved. A broad 
typology is presented which makes a distinction between 
medicinal products that have a marketing authorisation (i.e. 
they have been authorised by a regulatory body as a medicinal 
product) and other cannabis preparations that have not been 
authorised for medical use (see Figure 1).
What evidence is there that cannabis and 
cannabinoids have medical uses?
A summary of the evidence on the medicinal properties 
of cannabis and cannabinoids from systematic reviews of 
randomised controlled clinical trials is presented in the first 
part of the report.1,2 The report notes that interest in potential 
medical uses was only revived in the 1990s following the 
discovery of a cannabinoid system in the brain. This discovery 
suggested that cannabinoids could be used to treat chronic 
pain and neurological disorders such as multiple sclerosis and 
epilepsy. Therefore, it is acknowledged that there are gaps in 
the current evidence base and large well-conducted studies 
are scarce. See Table 1 for a summary of the key findings of the 
review of systematic reviews.
What approaches have countries used?
Overall, the report highlights the variation in approaches taken 
to allow access to cannabis and cannabinoids for medicinal 
use both within Europe and globally. They varied not only in 
terms of the actual products or preparations allowed, but also 
the regulatory frameworks adopted to control their provision. 
Three broad types of approach were identified, with countries 
often using more than one in parallel.
1 Allowing the use of medicinal products containing 
cannabinoids: Some countries have given market 
authorisation to medicinal products, thereby making them 
available for prescription.
2 Allowing the medical use of unauthorised products 
or preparations: Special access schemes have been 
established in some countries to allow for the medical use 
of unauthorised products or preparations. For example, it 
has been done as an interim measure while awaiting the 
findings of a clinical trial for a product or its authorisation. 
Others are made available on compassionate grounds 
and on a case-by-case basis. Physicians’ reluctance 
to prescribe for ethical and medico-legal reasons has 
presented major challenges to this approach.
3 De novo stand-alone medical cannabis programmes: 
Some countries have set up programmes that are outside 
the medicines regulatory systems. For example, in the 
United States the regulatory requirements for medicines 
were avoided by passing referendums allowing access to 
cannabis for broadly defined medical reasons. The authors 
note that this approach does not facilitate the conduct 
of clinical trials or establish an evidence base on which to 
assess the impact of these programmes.
What are the regulatory challenges?
The final part of the report highlights some of the regulatory 
challenges in allowing the medical use of cannabis and 
cannabinoids – in this context the authors are not talking about 
medicinal products rather cannabis preparations. They identify 
a number of questions, including:
• What types of products or preparations should be allowed? 
• What forms should be allowed? For example, raw cannabis, 
magistral preparations made by a pharmacist, or others 
such as standardised cannabis extracts or oils?
• What routes of administration will be permitted? For 
example, oral or vaporised forms?
• For which medical conditions should treatment be 
available? Governments could limit access to those 
experiencing medical conditions for which there is 
evidence of efficacy, or take a broader approach where 
approval would be given for any conditions which some 
patients have reported benefits.
• Who would be allowed to prescribe the products? Would 
this be limited to a specialist physician or would any medical 
practitioner be able to do so?
• How would the government deal with any possible 
reluctance of practitioners to prescribe cannabis for any 
ethical or medico-legal reasons?
• Who will pay for the products or preparations? The 
patients, national healthcare system or health insurance 
schemes?
• What types of quality standards should be applied to the 
products? How would they be monitored and enforced?
• How will the necessary pharmacovigilance schemes and 
data collection for the International Narcotics Control 
Board be organised?
7
Issue 69 | Spring 2019      drugnet IRELAND      
Medical use of cannabis  continued
Table 2: Availability of medicinal products containing cannabis or cannabinoids in Ireland (February 2019)
Product Nabiximols Nabilone Dronabinol
Under which Schedule is it regulated?a 4, part 1 2 1
Can it be prescribed in Ireland? Yes Yes Yes
Does it have marketing authorisation in Ireland? Yes No No
Does it require a ministerial licence to be prescribed? No No Yes
Can it be bought in Ireland? Yesb Yesc No
Does it need to be purchased abroad and imported on a case-by-case basis? No Yes Yes
Source: Department of Health, personal contact
a The Misuse of Drugs Regulations 1988 fall under the Misuse of Drugs Acts, which have been amended on several occasions since 1988. They divide controlled 
drugs into five schedules according to their ‘potential for abuse and their therapeutic usefulness’ (http://www.hpra.ie/homepage/controlled-substances/
controlled-substances/legislation). They apply varying controls on their production, supply, importation, and exportation. Schedule 1 controlled drugs have 
the most restrictions imposed; Schedule 5 the least.
b Nabiximols can be sourced by a pharmacist via wholesalers. 
c Nabilone can be sourced by a pharmacist via wholesalers and imported as an exempt medicinal product (EMP). However, difficulties arose over its supply,       
and in 2016 the Primary Care Reimbursement Service (PCRS) advised that it would not be approved for new patients. See PCRS circular 039/16:   
www.hse.ie/eng/staff/pcrs/circulars/pharmacy/exemptmedicinalproductarrangements0392016.pdf
Table 1: Summary of the evidence for the medical use of cannabis and cannabinoids 
Disease/symptoms Products tested Strength of evidence Limitations 
Nausea and vomiting associated with 
cancer chemotherapy 
Cannabinoids Weak Few studies testing against newer, 
more effective anti-emetics. 
Newer chemotherapy regimens 
produce less nausea. 
Little evidence available about use 
in other types of nausea. 
Appetite stimulant in patients with 
AIDS-related wasting 
Dronabinol/THC Weak Fewer AIDS-related cases available 
to treat now. 
Little evidence available about use 
to stimulate appetite in people with 
other conditions. 
Muscle spasm in patients with multiple 
sclerosis
Nabiximols Moderate Patients report reductions, but 
more limited impact on clinician 
ratings.
CNCP, including neuropathic pain Cannabis and 
cannabinoids
Moderate Small (but statistically significant) 
effect compared with placebo.
Palliative care for cancer Cannabinoids Insufficient Larger, better-designed trials are 
needed.
Intractable childhood epilepsy Cannabidiol Moderate Evidence for use in adjunctive 
therapy in people with Dravet or 
Lennox–Gastaut syndrome.
More studies are needed to look 
at dosage, interactions and use in 
people with other forms of
epilepsy.
Other medical uses, such as sleep 
disorders, anxiety disorders, 
depression, degenerative neurological 
disorders, and inflammatory bowel 
disease
Cannabis and 
cannabinoids
Insufficient Some evidence for short-term 
effects in some conditions (e.g. 
sleep disorders) but larger, better-
designed trials are needed, with 
longer follow-up.
Source: EMCDDA, 2018, p. 141
THC = tetrahydrocannabinol; CNCP = chronic non-cancer pain. CBD = cannabidiol.
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Access to other cannabis products (containing 
tetrahydrocannabinol (THC) and cannabidiol (CBD)) in 
Ireland, February 2019
Can cannabis products that contain THC be accessed in 
Ireland? 
Yes. Under Ireland’s Misuse of Drugs legislation, products 
containing THC are strictly controlled and possession 
is unlawful, except under ministerial licence. Under the 
legislation, it is open to the Minister for Health to consider 
granting a licence to an Irish-registered medical practitioner 
for medical cannabis for a named patient. As of 29 
November 2018, 12 such licences had been granted.4
From where are cannabis products containing THC 
sourced?
Where a product containing THC has been prescribed and 
a licence secured, it has to be sourced from outside Ireland. 
It is a matter for the prescriber and their patient to source 
it. It is understood that patients who have been prescribed 
such products have sourced them from a pharmacy in the 
Netherlands. 
Can cannabis products that contain CBD be accessed in 
Ireland? 
CBD is not controlled under Ireland’s Misuse of Drugs 
legislation. Therefore, products containing only CBD do not 
require a ministerial licence for use.
Figure 1: Cannabis and cannabinoids used for medical purposes – a broad typology
Source: EMCDDA, 2018, p. 81
Medicinal products
with marketing 
authorisation
Cannabis 
preparations
Cesamet and 
Canemes
Containing 
nabilone
Synthetic 
cannabinoid similar 
to THC
Raw cannabis
Marinol and 
Syndros
Containing 
dronabinol
Synthetic THC
Magistral 
preparations
Sativex
Containing 
nabiximols
Plant-based approx. 
equal quantities 
CBD/THC
Standardised 
cannabis 
preparations
Epiliodex
Containing 
cannabidiol
Plant-based CBD
Examples of medicinal products and their active ingredients
Variable in THC/CBD composition
Concluding comment
As with other EU countries, this is a topic that has attracted 
a lot of attention in Ireland and which is currently evolving 
under the work of the Expert Reference Group to advise on 
the development of a Medical Cannabis Access Programme.3 
While Ireland is not specifically mentioned in the report when 
it discusses the approaches currently being used, the findings 
suggest a fit with a combination of allowing the use of medicinal 
products containing cannabinoids and allowing the use of 
unauthorised products or preparations (see Table 2 and Box 1).
Lucy Dillon
1 European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) (2018) Medical use of cannabis and cannabinoids: 
questions and answers for policymaking. Luxembourg: Publications 
Office of the European Union.    
https://www.drugsandalcohol.ie/30034/ 
2 Hall W (2018) A summary of reviews of evidence on the efficacy 
and safety of medical use of cannabis and cannabinoids. Lisbon: 
European Monitoring Centre for Drugs and Drug Addiction. 
https://www.drugsandalcohol.ie/30208/ 
3 For further information, visit:    
https://health.gov.ie/cannabis-for-medical-use/  
4 See Dáil Éireann debates:     
https://www.oireachtas.ie/en/debates/question/2018-11-29/164/
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Civil society 
involvement in 
policymaking
Civil society involvement (CSI) in the development and 
implementation of drug policy is widely considered best 
practice and promoted at both international and national 
levels. For example, a focus on the value of CSI is evident in 
both the EU drugs strategy 2013–20201 and the EU action plan 
on drugs 2017–2020.2 One of the 15 objectives of the latter is 
to ‘ensure the participation of civil society in drugs policy’. It 
is also a key part of Ireland’s national drugs strategy, Reducing 
harm, supporting recovery: a health-led response to drug and 
alcohol use in Ireland 2017–2025.3
In line with this strategic approach, the Civil Society 
Involvement in Drug Policy (CSIDP) project is supported by 
the European Commission under its European Civil Society 
Involvement Project.4 It comprises a group of organisations 
working in the field of CSI at national and European levels.5 It 
aims to support CSI in the development and implementation 
of drug policies at national and European levels. To do so, it 
has set out to provide stakeholders with guidance to stimulate 
and support effective CSI, as well as raise awareness on the 
relevance and importance of CSI at national and European 
levels. It has produced three outputs that should be of interest 
to both those in Ireland working in the area of drug policy and 
civil society organisations (CSOs):
• An assessment report of CSI in drug policy in EU member 
states6
• A national action plan report on Ireland7
• A road map for effective CSI in drug policy.8 
Benefits of CSI
It is useful to reiterate the internationally recognised benefits 
of a CSI approach to policy which are outlined in these reports. 
By engaging with CSOs, policymakers get an understanding 
of what is happening on the ground. They are then better 
placed to develop timely policies that are relevant to the 
ever-changing drug situation in their country. The exchange 
of information also encourages innovative thinking and new 
approaches to tackling problems, as well as an insight into the 
challenges and opportunities experienced by those working 
under existing policy structures. CSI can increase buy-in 
for a particular policy by both those who will be required to 
implement them and those at which they are aimed – ‘when 
civil society is involved, popular legitimacy increases’ (p. 7).8 
It can lead to empowerment and increased participation 
among people who use drug services and hold policymakers 
accountable in ensuring that their civil and human rights are 
protected.
Assessment report and national action plan
The assessment report set out ‘to gain a better insight and 
create a better understanding of the nature and extent of 
civil society involvement in drug policy at the national level’ (p. 
4).6 Across the member states, it looks at three elements: the 
extent to which civil society features in national drug strategy 
documents; the number of CSOs and the level of CSI in various 
areas of policy development and implementation; and an 
analysis of the barriers and facilitators to CSI.
 
European experience
The bulk of the report focuses on the second element. It is 
an account of responses to a detailed questionnaire aimed at 
making an assessment of CSI in national drug policy in general, 
and the development and implementation of each country’s 
drug strategy.9 It examines different levels of involvement 
(information, consultation, dialogue and partnership) (see 
Figure 1) across the different policy areas (prevention, 
treatment, harm reduction, law enforcement and legal 
framework). As could be expected, there was a lot of variation 
across the member states, making it challenging to draw 
comparisons and conclusions from the data. Despite this, three 
of the top-line findings, when considering the majority of the 
member states, were: 
• Harm reduction represents the drug policy field with the 
highest level of CSI, and the fields of law enforcement and 
the legal framework are those with the lowest level.
• The level of CSI is generally higher during the 
implementation phase of policy than the development 
phase.
• There seems to be a lack of formal structures that support 
regular CSI in the development and implementation of drug 
policy.
Irish experience
Overall, the findings suggest that Ireland fares well in its 
experience of CSI. It does not appear to face the challenges 
that exist in some other member states. For example, the 
full range of levels of CSI in Ireland is reported to exist, 
from information to partnership, and it is seen as having a 
‘somewhat high’ level of CSI in drug policy (see Figure 2). This 
positive picture of Ireland as an environment where there 
is CSI in drug policy is echoed in the National Action Plan 
(NAP) Report for Ireland.7,10 It notes that CSOs ‘have long been 
involved in the response to drugs and drug use in Ireland’ (p. 6)7 
and found that there were good structures in place to facilitate 
CSI in drug policy – in particular those developed under the 
national drugs strategy, Reducing harm. 
In general, it is fair to say that the new strategy has 
been positively received by civil society actors, that 
state structures are open and supportive of civil 
society participation, and that there has been a good 
amount of work focused on participation in the first 
year of the strategy’s implementation. (p. 13)7
However, it was also noted that there was a need to provide 
supports to ensure that these structures were used to their full 
effect in delivering CSI. Existing structures could be improved 
to increase direct participation and ownership by stakeholders 
and citizens, including people who use drugs (PWUD), members 
of the Travelling community and other minority communities, 
and young people. There was also a call to ensure that key 
decisions linked with the national drugs strategy are made 
within the relevant participative structures, and that there is 
CSI on any working groups established under the strategy.
Road map
The CSIDP’s road map is aimed at both policymakers and 
CSOs.8 Its main objective is ‘to provide guidance through the 
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sustainable civil society structures in the field of drug policy 
on the local, regional and national level, as informed by the 
best available evidence’ (p. 5). The road map is divided into 
three parts:
1 How to assess current levels of CSI in drug policy in a 
country.
2 What policymakers can do to enhance CSI – from 
implementing different mechanisms of CSI to funding 
CSOs and research.
3 What CSOs can do to enhance CSI – from addressing 
possible structural issues to planning advocacy activities.
The authors emphasise the need for input from both 
policymakers and CSOs if the CSI is to be meaningful. It is 
recognised that policymakers might be more hesitant about 
working in this way, so CSOs need to be proactive and be 
prepared to take a leading role in getting the process going. 
Essentially, the authors recommend two main things: an 
assessment of the existing level of CSI; and a structured 
approach to improving areas that are not working so well, with 
mutual agreement on actions that need to be carried out by 
policymakers and CSOs accordingly. The road map contains 
numerous toolkits and guidance sources for stakeholders to 
draw on. A detailed description of the guidance is beyond 
the scope of this article and it is recommended that those 
working in this field access the full report. 
Lucy Dillon
1 Council of the European Union (2012) The EU drugs strategy 
2013–2020. Brussels: Council of the European Union.  
https://www.drugsandalcohol.ie/19034/ 
2 European Commission (2017) EU action plan on drugs 2017–2020. 
Brussels: Council of the European Union.   
https://www.drugsandalcohol.ie/27680/
3 Department of Health (2017) Reducing harm, supporting 
recovery: a health-led response to drug and alcohol use in 
Ireland 2017–2025. Dublin: Department of Health.  
https://www.drugsandalcohol.ie/27603/
4 For further information, visit: https://csidp.eu/
5 Ana Liffey Drug Project (ALDP) is a member of the group. 
6 Lahusen H, Verthein U and Martens M-S (2018) Civil society 
involvement in drug policy in EU member states. Assessment 
report. Amsterdam: De Regenboog Groep/Correlation Network. 
https://www.drugsandalcohol.ie/29890/
7 Keane M, Crook L and Vieru C (2018) Ireland National Action 
Plan Report. Dublin: Ana Liffey Drug Project.
8 Lahusen H, Keane M, Crook L, Košir M, Schiffer K, Ronconi S, et 
al. (2018) Civil society involvement in drug policy – a road map. 
Amsterdam: De Regenboog Groep/Correlation Network.  
https://www.drugsandalcohol.ie/29890/
9 The questionnaire was completed by representatives of one or 
more of the following bodies across the member states: a CSO, 
National Focal Point of the Reitox network, and administrative 
bodies with responsibility for drug policy. In Ireland, data were 
collected from a representative of the first two bodies.
10 An activity of the CSIDP was for five partner agencies to carry 
out a national action plan in their home countries: Bulgaria, 
Ireland, Italy, the Netherlands, and Portugal.
Civil society: This can be thought of as the associational 
life operating in the space between the state and the 
market – that is, not the public sector and not the 
private sector. Typically, it is understood to include 
the activities of non-governmental, voluntary and 
community organisations, but can also include individual 
participation. 
Civil society organisations (CSOs): Those organisations 
operating in civil society.
Civil society involvement (CSI): The process or practice 
of including civil society in policy development, setting, 
and implementation.
Civil society continued
Source: Lahusen et al. (2018) Civil society involvement in drug policy in EU 
member states. Assessment report, p. 13
Figure 1: Defining information, consultation and active participation
Source: Lahusen et al. (2018) Civil society involvement in drug policy – a road 
map, p. 16
Information Consultation Active Participation
Figure 2: Level of CSI in drug policy in general by country 
  Very high (2 countries)
  Somewhat high (10 countries)
  Neither high nor low (6 countries)
  Somewhat low (10 countries)
  No involvement at all (0 countries)
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Taking stock: a decade 
of drug policy
The International Drug Policy Consortium (IDPC) is a global network 
of 180 non-governmental organisations.1 It focuses on issues 
related to drug production; trafficking and use; and promoting 
objective and open debate on the effectiveness, direction and 
content of drug policies at national and international levels. The 
network supports evidence-based policies that are effective 
at reducing drug-related harm. As part of this work and in the 
context of the role identified by the work of the United Nations 
Office on Drugs and Crime (UNODC) for civil society involvement 
in drug policy,2 the IDPC has published Taking stock: a decade of 
drug policy.3 This report ‘evaluates the impacts of drug policies 
implemented across the world over the past decade, using data 
from the United Nations (UN), complemented with peer-reviewed 
academic research and grey literature reports from civil society’ 
(p. 7).3
2019 target date
The report focuses on the Political Declaration and Plan of Action 
on International Cooperation towards an Integrated and Balanced 
Strategy to Counter the World Drug Problem, which was adopted 
by UN member states in 2009.2 It includes measures to enhance 
international cooperation, identifies problems and areas requiring 
further action, as well as goals and targets in countering the world 
drug problem. The year 2019 was set as the target date for member 
states to ‘eliminate or reduce significantly and measurably’ five 
target areas: the illicit cultivation; demand; production, trafficking 
and use of internationally controlled substances; the diversion 
and illicit trafficking of precursors; and money laundering (p. 14).2 
IDPC argues that despite the Commission on Narcotic Drugs (CND) 
session due to take place in March 2019 and which aims to take 
stock of progress made on this plan, ‘no comprehensive review of 
the impacts of drug policies worldwide has yet been undertaken’ 
(p. 7).3 IDPC’s report seeks to fill this gap.
Findings
The report is a detailed presentation of the data exploring progress 
not only against the five target areas, but also in assessing progress 
towards the broader priorities of the UN – protecting human 
rights, promoting peace and security, and advancing development. 
The overall conclusion of the report is that the five target areas 
set in the 2009 Political Declaration and Plan of Action have 
not been achieved. Furthermore, it found evidence that many 
counterproductive policies have been put in place and they have 
made the situation worse, including when considering the UN’s 
broader priorities. The authors identify three main issues when 
reflecting on the evaluation of global drug policies:
• There is a need to conduct more thorough and regular 
research on the broader range of impacts of drug policies at 
local, national, regional and international levels.
• Where formal evaluations are being carried out, they tend to 
rely on government reporting. IDPC would encourage a more 
comprehensive and balanced approach, whereby civil society 
and academic research would also be included. It argues that 
this is particularly important for sensitive issues related to drug 
policy and human rights.
• Member states should reconsider what is being measured 
when assessing the impact of drug policy. IDPC suggests a 
move away from targets that focus solely on the illegal drug 
market towards an approach that takes account of the key UN 
Charter commitments to health, human rights, development, 
peace and security. 
Recommendations
In the final part of the report, IDPC identifies new indicators for 
measuring the success of global drug policy and makes a set of 
recommendations which it hopes will ‘provide a useful starting 
point for further discussions as to which goals and metrics could 
be considered for the post-2019 global drug strategy’ (p. 12).3 The 
recommendations as they appear in the report (p. 133) are:
• The international community should consider adopting more 
meaningful goals and targets in line with the 2030 Agenda for 
Sustainable Development, the UNGASS Outcome Document 
and international human rights commitments, and move away 
from targets seeking to eliminate the illegal drug market.
• Post-2019, member states should meaningfully reflect upon 
the impacts of drug control on the UN goals of promoting 
health, human rights, development, peace and security – and 
adopt drug policies and strategies that actively contribute to 
advancing the 2030 Agenda for Sustainable Development, 
especially for those most marginalised and vulnerable.
• Global drug policy debates going forward should reflect the 
realities of drug policies on the ground, both positive and 
negative, and discuss constructively the resulting tensions with 
the UN drug control treaties and any human rights concerns 
associated with drug control efforts.
Beyond 2019, UN member states should end punitive drug control 
approaches and put people and communities first. This includes 
promoting and facilitating the participation of civil society and 
affected communities in all aspects of the design, implementation, 
evaluation and monitoring of drug policies. 
Concluding comment
The report highlights the complexities involved in developing, 
implementing, and evaluating a plan like this globally, with such 
disparate political, economic and social contexts and responses 
to the situation at national level. However, it also provides valuable 
insights into measures and indicators that might be considered 
at national level to assess the impact and consequences of policy 
choices. Ireland is mentioned specifically in a number of places in 
the report. This tends to be when illustrating a health-led approach 
to dealing with drug use: explicitly addressing the issue of chemsex 
in our national strategy; providing naloxone training for prisoners; 
exploring decriminalisation for personal use; having a pilot project 
on medical cannabis; and CityWide’s ‘Stop the Stigma’ campaign.4
Lucy Dillon
1 For further information, visit: www.idpc.net. CityWide Drugs Crisis 
Campaign and Ana Liffey Drug Project are members of the IDPC 
network.
2 United Nations Office on Drugs and Crime (UNODC) (2009) Political 
declaration and plan of action on international cooperation towards 
an integrated and balanced strategy to counter the world drug 
problem. Vienna: UNODC. https://www.drugsandalcohol.ie/30219/ 
3 International Drug Policy Consortium (IDPC) (2018) Taking stock: 
a decade of drug policy – a civil society shadow report. London: 
International Drug Policy Consortium.    
https://www.drugsandalcohol.ie/29843/ 
4 CityWide’s campaign messages and materials can be accessed at: 
https://www.citywide.ie
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19 PREVALENCE AND CURRENT SITUATION 
Trends in alcohol and 
drug admissions to 
psychiatric facilities
Activities of Irish psychiatric units and hospitals 2017,1 the 
annual report published by the Mental Health Information 
Systems Unit of the Health Research Board, shows that the 
number of new admissions to inpatient care for alcohol 
disorders has continued to stabilise.
In 2017, some 1,147 cases were admitted to psychiatric facilities 
with an alcohol disorder, of whom 437 were treated for the first 
time. Figure 1 presents the rates of first admission between 1997 
and 2017 for cases with a diagnosis of an alcohol disorder. The 
admission rate in 2017 was similar to the previous year, while 
trends over time indicate an overall decline in first admissions. 
One-third of cases hospitalised for an alcohol disorder in 
2017 stayed just under one week, while 31% of cases were 
hospitalised for between one and three months, similar to 
previous years.
In 2017, some 896 cases were admitted to psychiatric facilities 
with a drug disorder. Of these cases, 414 were treated for the 
first time. Figure 2 presents the rates of first admission between 
1997 and 2017 of cases with a diagnosis of a drug disorder. 
Although the rate decreased slightly in 2017, there has been 
an overall increase in the rate of first admission with a drug 
disorder since 2011. It should be noted that the report does 
not present data on drug use and psychiatric comorbidity, so it 
is not possible to determine whether or not these admissions 
were appropriate.
Other notable statistics on admissions for a drug disorder in 
2017 include the following:
• Less than one-half of cases hospitalised for a drug disorder 
stayed under one week (46%), while 99% were discharged 
within three months. It should be noted that admissions and 
discharges represent episodes or events and not persons.
• 13% of first-time admissions were involuntary.
• Similar to previous years, the rate of first-time admissions 
was higher for men (13.7 per 100,000) than for women (3.8 
per 100,000).
Figure 1: Rates of psychiatric first admission of cases with a diagnosis of an alcohol disorder per 100,000 of population in Ireland, 1997–2017
Source: Daly and Craig, 2018
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Figure 2: Rates of psychiatric first admission of cases with a diagnosis of a drug disorder per 100,000 of population in Ireland, 1997–2017
Source: Daly and Craig, 2018
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Admissions to psychiatric 
facilities continued
Global, regional 
and country level 
estimates of HCV 
infection among 
recent injecting drug 
users
The World Health Organization has set a goal to eliminate 
hepatitis C virus (HCV) as a global public health threat by 2030. 
Targets include reducing new HCV infections by 80% and the 
number of HCV deaths by 65%, and increasing HCV diagnoses 
from 20 to 90% and eligible people receiving HCV treatment 
from <5 to 80%.1 Unsafe injecting drug use is the main route of 
HCV transmission in developed countries.2 Consequently, people 
who inject drugs (PWID) represent a priority population for HCV 
elimination, given the high prevalence and incidence in this 
group.
There are no previous global estimates of HCV prevalence 
among people with recent injecting drug use. Data on these 
are needed in order to monitor the progress of global HCV 
elimination efforts and to identify high-burden settings which 
should be targeted. A recent study estimated the prevalence and 
number of people with recent injecting drug use living with HCV, 
and the proportion of people with recent injecting drug use 
among all people living with HCV infection, at global, regional and 
country levels.3
In this research, published in the journal Addiction, data from a 
global systematic review of injecting drug use and HCV antibody 
prevalence among people with recent (previous year) injecting 
drug use were used to estimate the prevalence of people with 
recent injecting drug use living with HCV. These data were then 
combined with a systematic review of global HCV prevalence to 
estimate the proportion of people with recent injecting drug use 
among all people living with HCV.
Results
Global and regional estimates
Globally, it was estimated that in 2015, 39.2% (95% CI: 31.6–47.0) 
of people with recent injecting drug use had HCV viraemic 
infection, representing 6.1 million subjects (95% CI: 3.4–9.2) with 
recent injecting drug use living with HCV infection. Of the 71.1 
million (95% CI: 62.4–79.4) people living with HCV infection, it was 
estimated that 8.5% (95% CI: 4.6–13.1) were recent injecting drug 
users, with the greatest proportion in North America (30.5%), 
Latin America (22.0%) and Eastern Europe (17.9%).
European and Irish estimates
Global, Eastern/Western European and Irish estimates are shown 
in Table 1. For the Republic of Ireland, it was estimated that in 
2015, 56% (95% CI: 52.5–59.4) of subjects with a history of recent 
injecting drug use had HCV infection, representing 5,000 (95% 
CI: 3,500–6,000) individuals. Of the total number of people with 
Seán Millar
1 Daly A and Craig S (2018) Activities of Irish psychiatric units and 
hospitals 2017: main findings. HRB Statistics Series 38. Dublin: 
Health Research Board. https://www.drugsandalcohol.ie/29345/
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Table 1: Global, European and Irish estimates of the prevalence of HCV viraemic infection among people with recent injecting drug use, the 
number of people with recent injecting drug use living with HCV viraemic infection, the total population living with HCV viraemic infection, 
and the proportion of people with recent injecting drug use among the total population with HCV viraemic infection
Prevalence of HCV 
viraemic infection 
among people with 
recent injecting drug 
use (%)
Number of people with 
recent injecting drug 
use living with HCV 
viraemic infection (n)
Total population living 
with HCV viraemic 
infection (n)
Proportion of people 
with recent injecting 
drug use among the total 
population with HCV 
viraemic infection (%)
Global 39.2 (31.6–47.0) 6,063,500 
(3,434,500–9,246,000)
71,146,000 
(62,472,000–79,404,000)
8.5 (4.6–13.1)
Eastern Europe 48.6 (42.0–55.2) 1,466,500 
(699,500–2,377,000)
8,181,000 
(6,304,000–8,250,000)
17.9 (8.2–30.9)
Western Europe 39.9 (35.7–44.1) 402,500 
(264,500–557,000)
2,347,000 
(1,969,000–3,289,000)
17.2 (9.9–30.4)
Republic of 
Ireland
56.0 (52.5–59.4) 5,000 
(3,500–6,000)
29,500 (20,000–42,500) 16.2 (10.0–28.9) 
Source: Grebely et al., 2019
HCV infection in Ireland in that year (n=29,500, 95% CI: 20,000–
42,500), it was estimated that 16.2% (95% CI: 10.0–28.9) were 
individuals who had recently injected drugs.
Conclusions
The authors noted that there were wide variations among regions 
and countries with regard to HCV prevalence among recent 
injecting drug users and the proportion of injecting drug users 
among the total population with HCV infection. They suggest 
the research highlights that concerted efforts will be required 
in countries with large numbers of people infected with HCV in 
order to achieve global HCV elimination among PWID.
Seán Millar
1 World Health Organization (WHO) (2017) Global hepatitis report, 
2017. Geneva: WHO. https://www.drugsandalcohol.ie/27177/  
2 Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak 
D, et al. (2011) Global epidemiology of hepatitis B and hepatitis C 
in people who inject drugs: results of systematic reviews. Lancet, 
378(9791): 571–83. https://www.drugsandalcohol.ie/15845/ 
3 Grebely J, Larney S, Peacock A, Colledge S, Leung J, Hickman M, et 
al. (2019) Global, regional, and country–level estimates of hepatitis 
C infection among people who have recently injected drugs. 
Addiction, 114(1): 150–66.     
https://www.drugsandalcohol.ie/29394/ 
HCV infection among recent 
injecting drug users continued
Rates of reported 
codeine-related 
poisonings and 
codeine prescribing 
following new national 
guidance in Ireland 
The risks of misusing opioid medication have been well 
documented1,2,3 and include a wide range of problematic 
consumption outside of medical guidelines. Misuse can include 
consumption to induce psychoactive effects, use in combination 
with other drugs to alter their effects, or self-medication by 
increasing or lengthening duration of dosage without or against 
medical advice. Such risky behaviour can lead to adverse 
consequences, including dependence and/or poisoning. Despite 
the known risks, many countries, including Ireland, continue to 
permit codeine (an opiate to treat pain) to be available without 
prescription, over-the-counter (OTC). 
In order to address the public health issue of opioid misuse, in 
2010 the Pharmaceutical Society of Ireland (PSI) issued guidance 
in relation to the supply of codeine-containing products. The 
guidance, Non-prescription medicinal products containing 
codeine: guidance for pharmacists on safe supply to patients4, 
provided pharmacists with criteria to be adhered to when selling 
codeine, such as ensuring that codeine medicines only be 
supplied when deemed necessary by the pharmacist following 
consultation and only when a non-opioid analgesic has not 
proven sufficient to relieve the patient’s symptoms. If codeine is 
dispensed, the maximum dosage is a three-day supply following 
which the patient should be medically reviewed. 
Methods
In order to measure the impact of these guidelines, a recent 
study, published in the journal Pharmacoepidemiology and Drug 
Safety,5 examined two sets of data.
1 The National Poisons Information Centre (NPIC) database was 
used to assess poisoning rates related to codeine-containing 
products. NPIC advises healthcare professionals and the 
public on enquiries relating to poisonings. This database 
allowed the authors to quantify the reported incidences of 
15
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Codeine-related poisonings 
continued
codeine-containing products during the period 2005–2016. 
Using NPIC data, all codeine-related poisonings (non-
prescription and prescription) were plotted to measure 
occurrence pre- and post-2010 (when the guidance was 
issued).
2 The pharmacy claims database of the Health Service 
Executive Primary Care Reimbursement Service (HSE PCRS) 
was used to calculate trends in codeine prescriptions 
during the same period. This database contains information 
on all payments made to pharmacists in lieu of products 
dispensed to primary care patients entitled to reduced cost 
medicines. For the purposes of the study, all non-prescription 
co-codamol products (paracetamol and codeine) and 
two prescription only co-codamol products dispensed by 
pharmacies under the HSE PCRS scheme were considered. 
This would identify if there was an increase in those seeking 
alternative products or prescriptions for codeine-containing 
products due to the restriction in access to OTC codeine.
Results
Poisonings
Of the 1,851 reported codeine-related poisonings during the 
period 2005–2016, some 1,346 (73%) were available over the 
counter. Women made up the majority of case subjects (63%). 
Paracetamol and codeine was the most frequently reported 
combination (30%). Intentional poisoning was the most frequently 
reported event resulting in the poisoning and this remained 
unchanged when comparing the period 2011–2010. 
The majority of referral calls made to NPIC were from hospitals 
(51%), followed by general practitioner/family doctor (30%), and 
16% from the public. Overall, during the period 2005–2016, there 
was a 53% decrease in reported codeine-related poisonings. 
Non-prescription (OTC) codeine poisonings decreased by 62% 
during this period. 
In the year following the introduction of the guidelines (2011), a 
significant decrease (33%) was evident in poisonings involving 
non-prescription (OTC) codeine, after which there was little 
change in the rate of poisonings.
Prescriptions
Using a similar timeline (2006–2015), analysis of the HSE 
PCRS data showed no significant change in the number of 
reimbursements for prescription codeine-containing products or 
alternative OTC opioid medications when comparing before and 
after the introduction of the guidance. 
Conclusion
The new guidance on codeine supply coincided with an initial 
reduction in reported codeine poisoning cases, particularly OTC 
cases, and this may have been related to the restriction of same. 
However, the overall reduction was in keeping with previous 
trends, although of a larger magnitude. The rate of decline did not 
continue and has plateaued. There was no concurrent increase 
in the prevailing rate of prescription claims for these products or 
potential substitutes. 
The data highlight the impact of the guidelines and show that they 
are effective but only for a limited period of time, and, as such, 
further restrictions on codeine-related products may be required 
to improve public health outcomes.
Anne Doyle
1 Casati A, Sedefov R and Pfeiffer-Gerschel T (2012) Misuse of 
medicines in the European Union: a systematic review of the 
literature. Eur Addict Res, 18(5): 228–45.
2 Dalton P, Kennedy J and Weedle P (2009) Use and abuse of 
over-the-counter (OTC) medicines containing codeine in 
Ireland [Abstract]. Drug Utilisation Research Group (UK & Ireland) 
Conference 2009, London. Pharmacoepidemiol Drug Saf, 18(6): 523. 
3 Foley M, Carney T, Rich E, Parry C, Van Hout MC and Deluca P (2016) 
Medical professionals’ perspectives on prescribed and over-the-
counter medicines containing codeine: a cross-sectional study. BMJ 
Open, 6(7): e011725. https://www.drugsandalcohol.ie/25819/ 
4 Pharmaceutical Society of Ireland (PSI) (2010) Non-prescription 
medicinal products containing codeine: guidance for pharmacists 
on safe supply to patients. Version 1. Dublin: PSI.
5 Kennedy C, Duggan E, Bennett K and Williams DJ (2019) Rates of 
reported codeine-related poisonings and codeine prescribing 
following new national guidance in Ireland. Pharmacoepidemiol Drug 
Saf, 28(1): 106–111. https://www.drugsandalcohol.ie/30150/ 
Parole Board annual 
report, 2017
In October 2018, the Parole Board published its annual report.1 
This was the 16th annual report since the board was established 
in 2001. The aim of the Parole Board is to review the cases of 
prisoners who have received either ‘determinate’ sentences 
greater than or equal to eight years or life sentences and to 
provide guidance on how these sentences are managed. The 
current report provided an overview of the board’s activities 
for 2017. 
Issues relating to mental health among 
prisoners
Within the report, the problem of mental health in prisoners 
was highlighted. The board has acknowledged and provided 
support for recommendations put forward by the late Judge 
Michael Reilly in 2016.2 
Parole Board process
With the aim of increasing understanding of the Parole Board 
process, presentations in prisons across Ireland were made 
by board members. Prisoners were given the opportunity to 
take part in discussions and give feedback on the process. The 
board intends to continue these presentations with the aim of 
going to each prison biannually.
Parole Board process review
Delays between Parole Board reviews and not observing 
timelines were identified as issues that were not acceptable. It 
is hoped that these problems will be addressed once the Parole 
Bill 2016,3 which is currently progressing through the Houses of 
the Oireachtas, is enacted. This Bill provides for parole hearings 
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to occur within six months of the initial review date.
Prison visits
In 2017, the Parole Board met with groups of life-sentenced 
prisoners in eight prisons to discuss and clarify what was 
involved in the parole process and to encourage them to 
engage with the rehabilitation process. 
Victims and families
The report highlighted that prior to a prisoner review, 
correspondence was frequently received from victims and/or 
their families disclosing the level of pain and emotional suffering 
experienced as a result of the prisoner’s actions. These are 
taken into consideration before a recommendation is made.
Statistics
The report highlighted important statistics for 2017. Overall, 
there was a total caseload of 346. This figure included new 
cases and cases at second or subsequent stages of the review 
process. In addition, the following were noted:
• 66 cases were referred to the board for review, of which 
two were on remand for drug offences.
• 48 of the 66 prisoners invited to participate accepted an 
invitation to take part in the review process; one prisoner 
was on remand for drug offences.
• Three prisoners declined to take part, two of which were on 
determinate sentences.
• 15 invitations were not responded to, all of these were 
on determinate sentences. A possible explanation put 
forward for non-engagement is that prisoners in receipt of 
determinate sentences are automatically eligible for a 25% 
reduction in sentence.
The Parole Board met 11 times and 114 case recommendations 
Parole Board annual report, 2017 
continued
were made to the Minister for Justice and Equality:
• 102 case recommendations were accepted in full. 
• 21 of these case recommendations were life-sentenced 
prisoners who were granted parole on a phased basis.
• Three cases were accepted conditionally or in part. 
• Nine decisions were pending at year-end.
• 32 prisoners were reviewed for the first time.
• 82 prisoners were reviewed as part of second or 
subsequent reviews.
• 114 interviews were carried out by board members, of which 
32 were first reviews. Interviews are not viewed as essential 
for second or subsequent reviews; however, the board 
believes that an interview is sometimes in the best interests 
of the prisoner. 
Minister for Justice and Equality Charlie Flanagan TD 
acknowledged the level of work carried out by the Parole 
Board and thanked the chairman, Mr John Costello, and board 
members for their important contribution to the rehabilitation 
process.4 In addition, Minister Flanagan reiterated his verbal 
commitment to progress the Parole Bill 2016 through the 
Oireachtas to enable the Parole Board to achieve statutory 
status. This was welcomed by the Irish Penal Reform Trust.5
Ciara H Guiney
1 The Parole Board (2018) Annual report 2017. Dublin: The Parole 
Board. https://www.drugsandalcohol.ie/29764/ 
2 Reilly M (2016) Healthcare in Irish prisons. Dublin: Department of 
Justice and Equality. https://www.drugsandalcohol.ie/26885/ 
3 Parole Bill 2016. Available online at    
https://www.oireachtas.ie/en/bills/bill/2016/29/ 
4 Department of Justice and Equality (2018) Press release: Minister 
Flanagan publishes Parole Board annual report 2017. Available 
online at http://www.justice.ie/en/JELR/Pages/PR18000311
5 Irish Penal Reform Trust (2017) Press release: Parole Board annual 
report 2017. Dublin: Irish Penal Reform Trust. Available online at 
http://www.iprt.ie/contents/3338 
The authors note that the standards are presented in a 
context where there is a renewed emphasis on the health and 
wellbeing of people in international approaches to dealing 
with drug issues. These are, for example, in the United Nations 
(UN) Sustainable Development Goals to be achieved by 20303 
and the Outcome document from the 2016 United Nations 
General Assembly Special Session on the world drug problem 
(UNGASS).4 This has raised the profile of prevention in global 
drug policy and reinforces the need for prevention strategies 
to be based on a sound evidence base, which is sometimes 
lacking. The primary objective of prevention is defined as: 
…to help people, particularly but not exclusively of 
younger age, to avoid or delay the initiation of the use 
of psychoactive substances, or, if they have started 
already, to avert the development of substance use 
disorders (harmful substance use or dependence).  
(p. 2)2
RESPONSES
Updated international 
standards on drug 
use prevention
In 2013, the United Nations Office on Drugs and Crime (UNODC) 
published the first edition of its International standards on 
drug use prevention.1 The standards present an overview of 
the international evidence for prevention interventions and 
policies. A second, updated version produced in collaboration 
with the World Health Organization (WHO) is now available.2
17
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Methodology
The standards draw on a number of evidence sources. At their 
core is a summary of the current scientific evidence base 
gathered by means of an overview of recent systematic reviews, 
combined with the findings of a similar exercise upon which the 
first edition is based. They also draw on international expertise 
through the work of an international group of experts, and refer 
to existing guidance, in particular that of WHO.
The document should be a useful reference for policymakers 
and practitioners interested in the area of prevention. It does 
not go as far as making recommendations about specific 
programmes, instead it gives a brief description of: 
• The intervention or the policy, its main activities and 
theoretical basis 
• The available evidence from the systematic reviews on 
the intervention or policy, in particular its effects on 
primary (substance use) and secondary (mediating factors/
intermediate outcomes of prevention) outcomes
• The existing WHO guidance on the strategies 
• The characteristics of the strategies associated with 
efficacy and/or effectiveness, or lack thereof 
• A list of any relevant guidelines or tools for further 
information.
Interventions and policies are grouped by the developmental 
stage of the target group: pregnancy, infancy and early 
childhood (0–5 years); middle childhood (6–10 years); early 
adolescence (11–14 years); adolescence (15–18/19 years); and 
adulthood (20+ years). 
An effective prevention system
In the final section of the report, the authors outline the 
characteristics of an effective national drug prevention system, 
which has the overarching goal to support the healthy and safe 
development of individuals. They describe it as delivering ‘an 
integrated range of intervention and policies based on scientific 
evidence, in multiple settings, targeting relevant ages and levels 
of risk’ (p. 50).2 It would have strategies that have ‘a mix of 
environmental and developmental components, with a minor 
component focusing on information’ (p. 50).2 To be effective, 
the system needs to be underpinned by strong structural 
foundations. There are a number of elements to this, including:
• A supportive policy and legal framework that is health-
centred and which ensures the availability of controlled 
drugs for medical and scientific purposes, while preventing 
diversion and non-medical use. Elements of the framework 
would include: national (quality) standards for drug 
prevention interventions and policies; national professional 
standards for prevention policymakers and practitioners, 
possibly with an accreditation system; and policies requiring 
schools and employers to implement evidence-based 
programmes or policies. 
• Scientific evidence and research are key elements when 
making decisions about the elements of a prevention 
system, and ensuring those being delivered are having the 
desired impact.
• Coordination of multiple sectors and levels are required 
with clearly defined roles and responsibilities. This needs 
Drug prevention standards continued to be supported by effective infrastructure, for example, a clear mechanism that would provide decision-makers with 
strong technical assistance to guide them in implementing 
evidence-based policies and interventions.
• Training of policymakers and practitioners in prevention 
needs to be supported on an ongoing basis. The 
Coordinator Series of the Universal Prevention Curriculum5 
is identified in this context.
• Commitment to provide adequate resources and 
to sustain the system in the long term. This includes 
(financial) support for the interventions and those delivering 
them; the technical assistance required to support 
implementation and continuous quality improvements; 
and the academic and research institutions responsible for 
monitoring and evaluating the activities. 
Concluding comment
The prevention element of Ireland’s drug and alcohol strategy, 
Reducing harm, supporting recovery: a health-led response 
to drug and alcohol use in Ireland 2017–20256 fits well with 
the general approach outlined in the standards in terms of 
the national strategy’s overall health-centred objective: ‘To 
promote and protect health and wellbeing’ (p. 7). Similar to the 
primary objective of the standards, the Irish strategy
aims to protect the public from threats to health and 
wellbeing related to substance misuse by preventing 
early use of alcohol and other drugs among young 
people, influencing behaviour and challenging 
social norms and attitudes, and providing targeted 
interventions aimed at minimising harm for those who 
have already started to use substances.  (p. 17)6 
The standards should be useful in providing an overview of 
the range of interventions for which there is evidence of 
effectiveness and the nature of support required to deliver an 
effective system of prevention.
Lucy Dillon
1 United Nations Office on Drugs and Crime (UNODC) (2013) 
International standards on drug use prevention. Vienna: UNODC. 
https://www.drugsandalcohol.ie/19481/
2 United Nations Office on Drugs and Crime (UNODC) and World 
Health Organization (WHO) (2018) International standards on drug 
use prevention. 2nd edn. Vienna: UNODC.   
https://www.drugsandalcohol.ie/30048/
3 For further information on the goals, visit:   
https://www.un.org/sustainabledevelopment/sustainable-
development-goals/
4 United Nations Office on Drug and Crime (2016) Outcome 
document of the 2016 United Nations General Assembly Special 
Session on the world drug problem. Vienna: United Nations Office 
on Drug and Crime. https://www.drugsandalcohol.ie/27442/
5 For further information, visit:     
https://www.issup.net/training/universal-prevention-curriculum
6 Department of Health (2017) Reducing harm, supporting recovery: 
a health-led response to drug and alcohol use in Ireland 
2017–2025. Dublin: Department of Health.    
http://www.drugsandalcohol.ie/27603/
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Society on Addictions 
(IntNSA) Europe
On Sunday, 26 August 2018, a special ceremony linked to the 
10th International Council of Nurses (ICN) Nurse Practitioner/
Advanced Practice Nurses (NP/APN) conference took place at 
De Doelen Congress Centre in Rotterdam, the Netherlands. 
Addiction nurses from around the world gathered for the 
inauguration of the International Nurses Society on Addictions 
(IntNSA) Europe and the launch of the new website of the 
Netherlands Chapter of IntNSA.1 
During the four days of the conference, IntNSA members 
from the United States (US), the United Kingdom (UK), the 
Netherlands and Ireland, along with colleagues from the Drug 
and Alcohol Nurses of Australasia (DANA) and service-user 
representatives from the Netherlands, contributed to several of 
the conference workshops and presentations. Their objective 
was to increase awareness of education, best practice, and 
the role of the specialist nurse when addressing the needs of 
people who use drugs and alcohol. As the largest professional 
group in healthcare, nurses are uniquely placed to address the 
needs of this population across the continuum of care. 
During the conference, the Dutch Minister for Health, Hugo de 
Jonge, announced that advanced nurse practitioners (ANP) in 
the Netherlands will be allowed to work as fully autonomous 
practitioners. In the Netherlands, ANPs in addiction treatment 
can admit and discharge service users as well as initiate 
the prescribing of diamorphine and/or other substitute 
medications such as methadone. The value of specialist 
addiction nurses and specifically nurse prescribers in the 
UK, the US and Australia has also been realised, where they 
have significantly increased access to cost-effective and gold 
standard services.2 
In Ireland, we have a small number of trained nurse prescribers 
working in addictions, most of whom are not prescribing 
or else prescribing in a limited capacity. The new national 
drugs strategy3 has stipulated that the development of nurse 
prescribing should be explored further. This may lead to 
the necessary legislative changes being made to facilitate 
the development of this role, as has been done in other 
jurisdictions. 
More recently, the Nursing and Midwifery Planning and 
Development Units (NMPDUs) have funded research, led by 
Professor Catherine Comiskey from Trinity College Dublin, 
into the role of the nurse and ‘what service users want’ from 
nurses. From this, it is hoped that the full potential of the 
nurses to meet the needs of service users will be acknowledged 
and further developed. The Ireland Chapter of IntNSA is 
represented on our National Steering Committee and on the 
National Implementation Committee for the new national 
drugs strategy, and continues its involvement in international 
research. 
Peter Kelly
1 For further information, visit the website:   
https://www.intnsaholland.com 
2 For further information on the role of the nurse working in drug 
and alcohol treatment services in the UK, visit:   
https://www.gov.uk/government/publications/role-of-nurses-in-
alcohol-and-drug-treatment-services
3 Department of Health (2017) Reducing harm, supporting recovery: 
a health-led response to drug and alcohol use in Ireland 
2017–2025. Dublin: Department of Health.    
https://www.drugsandalcohol.ie/27603/
From L to R: Professor 
Trish Hafford-Letchfield, 
Middlesex University 
London; Dr Ginny 
Focht-New, IntNSA US; 
Jackie Middledorp, ANP, 
IntNSA Netherlands; 
Dr Chris Loth, IntNSA 
Netherlands; Dana 
Murphy-Parker, IntNSA 
US; Dr Stephen Strobbe, 
president of IntNSA 
Global; Yvonne Slee, 
ANP, president of IntNSA 
Netherlands; Dick van 
Etten, ANP, IntNSA 
Netherlands; Professor 
Carmel Clancy, IntNSA 
UK; Dr Adam Searby, 
secretary of DANA; Peter 
Kelly, IntNSA Ireland 
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Evaluation of three 
J-ARC pilot projects 
The Joint Agency Response to Crime (J-ARC) is a multiagency 
response to the management and rehabilitation of offenders. It 
was established by An Garda Síochána, the Irish Prison Service, 
the Probation Service, and the Department of Justice and 
Equality in 2014. The main aim of J-ARC is to stop crime and 
increase safety in society by targeting prolific offenders that are 
considered guilty of the majority of crimes. J-ARC presented 
the findings of an evaluation of the effectiveness of three pilot 
initiatives – ACER3, STRIVE, and Change Works – that were 
developed to reduce offending behaviour.1 Table 1 provides an 
overview of the main features of the three programmes.
Methodology
The evaluation involved a desk-based review, although a 
mixed methods approach was utilised across programmes 
and included structured surveys, face-to-face interviews with 
clients and practitioners, focus groups observation, and case 
studies. 
Results
Despite the small sample sizes, the available data allowed for 
an in-depth analysis of whether or not J-ARC was operating 
efficiently. The main finding was that J-ARC programmes were 
having a positive impact on offenders. Figure 1 shows the 
percentage of offenders who did not reoffend across the three 
J-ARC projects. The proportion of targets that did not reoffend 
was highest for Change Works, followed by STRIVE, then ACER3. 
It was not possible to determine which programme was more 
successful statistically. Other issues that also made comparison 
between programmes difficult included operational definitions 
for reoffending, evaluation periods, and differing offences 
targeted across projects. 
Limitations 
As acknowledged by the authors, a number of limitations were 
evident across the programmes.
• Sample sizes were small; hence, it was difficult to make 
strong statistical conclusions.
• No evaluation plan was identified at the start; hence, data 
collected were not gathered with evaluation in mind.
• No control group was utilised, so it was not possible to 
compare outcomes between those that received the 
intervention and those that did not. 
Despite these limitations, it is important to note that these 
evaluations were the first ones carried out by J-ARC and were 
done when the programme was still in development phase. The 
outcomes of these evaluations will inform the existing evidence 
base for future evaluations. 
Recommendations 
Based on the evaluations of the three programmes, a number 
of recommendations were made that could be applied across 
J-ARC projects. 
• The programme should be continued and expanded.
• The existing resources should be reviewed to enable an 
increase in J-ARC targets.
• Procedures should be developed to allow effective 
evaluation, data collection, and monitoring of J-ARC 
targets.
• There should be outcome monitoring and agreement on 
operational definitions.
• There should be a cost analysis of the J-ARC project.
• The initial selection and deselection should be reviewed 
and monitored.
• There should be clarification of the lead agency role 
and implementation of a process to consider changes in 
responsibility as the target status evolves.
• A secure and visible IT system should be in place to enable 
information sharing.
• There should be a clear benefits model outlining services 
available to targets.
• There should be early identification and involvement of 
stakeholders.
• An evaluation framework should be developed for future 
J-ARC projects.
• There should be training and communication to increase 
awareness and normality of J-ARC.
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ACER3 Change Works STRIVE
Figure 1: Percentage of offenders who did not reoffend
Source: J-ARC Evaluation Framework Working Group, 2018, pp. 28–29
Note: Reoffending is defined as ‘detection’ in ACER3; as a ‘new offence/
charge’ in Change Works; and as a ‘recorded offence’ in STRIVE. 
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Table 1: Summary of the key features of the three J-ARC pilot projects
ACER3 Change Works STRIVE
Number of targets during the 
evaluation period* 
10 targets in both locations 
(20 in total). Two targets were 
replaced 
50 ‘priority’ targets at 
programme launch in Q1 2015; 
51 ‘priority’ targets at end of 
Q2 2017 
18 key individuals during the 
time of the evaluation 
Location of targets D24 & D8 Tallaght & Kevin St 
stations 
Dublin Metropolitan Region East Ballymun 
Criminal profile of targets** Burglary and related offences Violent and harmful behaviour Most prolific offenders (total 
crimes) in specific area 
Location of intervention Various locations Bridge Centre Various locations around East 
Ballymun 
Start date of the project Q2 2015 Q1 2015 January 2015 
Other agencies involved Local drug treatment services 
along with training and 
employment programmes 
Bridge Project team Ballymun Social Regeneration 
Subcommittee, Job Centre, 
DSP, DCC and Local Drugs 
Taskforce 
Initial timescale of the 
project 
2-year pilot 2-year pilot 2-year pilot 
Evaluation period May 2015–Dec 2016 Jan 2016–Aug 2017 Jan 2015–Dec 2015 & July 
2016–Dec 2016 
Source: J-ARC Evaluation Working Group, 2018, p. 9
* The number of targets can fluctuate over time as people move in or out of the programme.
** Criminogenic behaviour and pathway treatments are clearly different for violent/harmful offenders compared to prolific offenders. This means comparing 
and evaluating Change Works with ACER3 and STRIVE may be challenging, although the latter two will have clear commonalities.
DSP = Department of Social Protection; DCC = Dublin City Council.
Evaluation of three J-ARC pilot 
projects  continued
Cross-border 
organised crime: 
threat assessment 
2018
In September 2018, An Garda Síochána (AGS) and the Police 
Service of Northern Ireland (PSNI) published their biannual 
cross-border organised crime threat assessment.1 The aim of the 
report was to provide insight into criminal activity on the island of 
Ireland. 
Abuse of Common Travel Area
The Common Travel Area (CTA), which exists between the 
Republic of Ireland (ROI) and the United Kingdom (UK), permits 
the free movement of goods, money, people and information. 
The CTA has mainly had a positive impact on individuals residing 
in both areas. However, the land border (approx. 224 miles) that 
lies between ROI and Northern Ireland (NI) is currently open 
and not subject to checks by customs or law enforcement. This 
leaves ROI and NI exposed to criminal activities, such as trafficking 
contraband and immigration crime, carried out by organised 
crime groups (OCGs). Another challenge noted is that the land 
border will also separate the UK from the European Union (EU) 
post-Brexit. In the event of the UK successfully leaving the EU, it 
is likely that OCGs will adapt to any changes that arise in the CTA; 
hence, cross-border criminality is expected to increase. That 
said, interagency cooperation will continue to target any abuse of 
the CTA that arises. 
Organised crime groups
It is estimated that approximately 50% of OCGs have strong 
relationships and interactions on both sides of the border. Cross-
border activity by mobile organised crime groups (MOCGs) are 
considered an all-island problem and have significant impact on 
Ciara H Guiney
1 J-ARC Evaluation Framework Working Group (2018) Critical review 
of initial evaluations on the three J-ARC pilot projects. Dublin: 
Department of Justice and Equality.    
https://www.drugsandalcohol.ie/29722/ 
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domestic burglary in both jurisdictions. The majority of MOCGs 
are thought to originate in Dublin and involve extended family 
networks. They have extensive skills, are organised, sophisticated 
and forensically aware, and illustrate elevated risk-taking 
behaviour on roads. At this stage, it is not known whether Brexit 
will have an impact on these groups. The Cross Border Joint 
Agency Task Force has allocated resources to address criminality 
by MOCGs via joint interagency action.
Cross-border organised crime: drugs
Similar to the 2016 assessment, the report has highlighted that 
drugs and drug-related criminality has remained a concern 
throughout the island. Although ‘traditional’ drug importation 
routes are unchanged, the emergence of the dark web along with 
new psychoactive substances (NPS) and misuse of prescription 
medications have resulted in changes in drug abuse and OCG 
criminality.
 ‘Traditional’ drugs remain prominent. For example:
• Cannabis continues to be the most prevalent drug used/
abused on the Island. At €29/£20 per gram, it is viewed 
by OCGs involved in wholesale importation and supply as 
profitable. Cannabis herb blocks or cultivated cannabis 
plants are mainly seized in ROI. However, other products, 
for example, cannabis resin and cannabis oil, have also been 
detained. Irish national OCGs are deeply implicated in this 
area controlling routes and grow houses.
• Improved economic conditions recently have resulted in 
increased demand for cocaine and MDMA. Although it is 
possible to sell these drugs on the darknet, they do form 
a small part of OCG importations. OCGs that participate 
in ‘poly drug dealing’ are mainly smaller than ‘traditional 
wholesale importers’. As a result, they can pose issues for law 
enforcement when trying to target the problem (p. 7).
• Heroin continues to be a problem across Ireland. While the 
most problematic area is Greater Dublin, in recent years 
similar problems have arisen in small urban centres and 
rural towns and villages. The majority of opiate users reside 
in Dublin (71%) and are over 35 years of age (>50%). Heroin 
issues in ROI are viewed as ‘stable and entrenched’ (p. 7). 
While in NI, the most problematic area is Belfast city centre, 
where drug use can be observed every day on the streets. 
• In contrast to previous assessments, crack cocaine has 
recently emerged as an issue for law enforcement agencies 
Cross-border organised crime: 
threat assessment 2018  continued
and communities. For now, it is not viewed as a nationwide 
issue, but it is believed that it will need to be targeted in the 
future.
• Synthetic opioids have been a characteristic of Irish OCG 
activity since 2016. Although reported seizures of these 
products are low, only 0.02 mg of synthetic opioid carfentanil 
is needed to produce a fatal overdose. While this is not a 
crisis in ROI and NI currently, there is evidence to suggest 
that OCGs are selling products on the premise that they 
are heroin but in actual fact are heroin mixed with synthetic 
opioids and/or bulking agents. 
• Another problem is that some OCGs are introducing synthetic 
opioids into the drug supply chain that is placing drug users at 
considerable risk. This problem has been identified as an area 
that requires ongoing attention and monitoring.
• Prescription medication is an issue across ROI and NI 
and involves the importation, manufacture and sale of 
pharmaceutical products. Benzodiazepines are popular in 
individuals using heroin, managing pain and trying to improve 
cognitive and/or physical function. 
• Another emerging trend is the use of amphetamines by 
individuals attending tertiary education. Targeting the 
illicit sale of these products is more and more challenging. 
However, as prescription drug abuse increases so too will be 
the issues around it.
Cross-border activity
Primarily, the cross-border elements of drug crime across Ireland 
centres on relationships between OCGs in ROI and NI in the areas 
of control and supply. Although the links between ROI and NI 
OCGs are extensive, collaboration among foreign national OCGs 
are stronger, as they see Ireland as one market. 
The most important supply route on the island is between 
Dublin and Belfast. This is due to excellent infrastructure linking 
both areas via motorways and transport systems. Irish OCGs 
make it possible for NI OCGs to access European drug markets, 
such as Spain, the Netherlands, and the UK. In consequence, 
joint collaborations between the PSNI and AGS often involve 
collaborating with international agencies with the aim of stopping 
drug supply routes north and south of the border.
Ciara H Guiney
1 Police Service of Northern Ireland and An Garda Síochána (2018) 
Cross border organised crime: threat assessment 2018. Belfast and 
Dublin: Department of Justice (UK) and Department of Justice and 
Equality (ROI). https://www.drugsandalcohol.ie/29908/ 
exposure to childhood trauma/ACEs and future negative health 
outcomes as well as increased risk of alcoholism, drug abuse, 
depression, and homelessness. 
Recent research examined the role of trauma and the 
implications for those affected on how they interact with 
services in Ireland.1 The study enrolled a group of women 
utilising a number of different services in Limerick. The women 
were profiled through research commissioned by the PALLS 
(Probation and Linkage in Limerick Scheme) project, as having 
considerable resilience and capacity for survival. The women all 
had significant experiences of childhood adversity and trauma. 
The aim of the work was to better understand the role of 
Resilience in the 
face of trauma: 
implications for 
service delivery
Psychological trauma, such as adverse childhood experiences 
(ACEs), can have significant effects on an individual’s physical 
and emotional health. There is a relationship between 
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drug and alcohol use, some women expressed the need for 
gender-specific services and for safe accommodation to aid 
in the recovery from problem substance use. Self-reported 
mental health issues were high among this group of women and 
they identified a number of barriers to accessing appropriate 
services. These included fear of child protection services, lack 
of trust in the service provider, and a need to access mental 
health services quickly. 
Differing views emerged between the service providers and 
the service users on the perceptions of the services provided 
in relation to factors of trauma-informed care, such as feeling 
valued, respected, safe, cared for, understood, and trusted. The 
service users and providers were both asked to rate services on 
these qualities. Service providers marked themselves higher for 
all the factors than the clients did, with the biggest difference 
observed in the value of respect. 
By acknowledging the role of trauma in individuals who go on 
to develop substance abuse, criminality and homelessness 
issues, and their subsequent interactions with these services, 
new evidence-informed strategies can be developed. These 
would be of use to services that are engaging with trauma 
survivors. Services can examine how they themselves interact 
with trauma survivors in order to improve how they deliver care 
to these women. This is to include an assessment of themselves 
as an organisation and to implement practices that create an 
environment where service users can engage, heal and grow. 
Helen Kennelly
1 Dermody A, Gardner C, Davis S, Lambert S, Dermody J and Fein 
M (2018) Resilience in the face of trauma: implications for service 
delivery. Irish Probation Journal, 15: 161–78.   
https://www.drugsandalcohol.ie/30005/
2 National Drugs Rehabilitation Implementation Committee (2011) 
National protocols and common assessment guidelines to 
accompany the National Drugs Rehabilitation Framework. Dublin: 
Health Service Executive. https://www.drugsandalcohol.ie/16717/
3 Further information is available at https://www.cdc.gov/
Aims/objectives and methodology
The evaluation was commissioned with the aim of assessing the 
effect of Tabor treatment programmes across all their facilities 
and to provide an independent examination of the efficacy of 
these programmes and the ‘goodness of fit’ of the treatment 
model. 
The evaluation comprised both desk-based research and 
primary data collection. The desk-based research involved 
an analysis of their annual reports from the period 2013–2017. 
The data collection was performed in two ways: there was a 
qualitative data component, involving interviews and focus 
groups, and a quantitative data component carried out through 
online anonymous submissions. The data collection took place 
from September 2017 to June 2018. 
In total, there were 58 submissions for the evaluation. This 
included 34 individual interviews, 7 focus group participants, 
and 17 individual written submissions. 
Evaluation of Tabor 
Group addiction 
services
The Tabor Group, a provider of residential and community-
based addiction treatments in Ireland, has conducted and 
published the results of an external evaluation of their services.1 
The Tabor Group comprises three residential units: Tabor 
Lodge (primary treatment centre), Fellowship House (secondary 
treatment centre for males) and Renewal (secondary treatment 
centre for females) using the Minnesota Model, as well as 
supported accommodation in the community. In 2017, some 213 
patients were admitted to their residential unit, Tabor Lodge, 
for treatment as well as providing structured support for their 
families. 
trauma, particularly how it affects the women’s interaction with 
service providers, and how service providers could incorporate 
this knowledge into service delivery. 
The objectives of this research were to gain a better 
understanding of the needs and experiences of the women 
utilising local drug, homeless and criminal justice services. The 
research was conducted through semi-structured interviews 
of female service users in eight different service providers in 
Limerick. The interviews used two frameworks to inform their 
questions: the National Drugs Rehabilitation Implementation 
Committee’s standards for care planning2 and the ACE study 
and definitions provided by the Centers for Disease Control and 
Prevention.3
An online survey was also part of the research, which was 
distributed to frontline staff in the different drug and alcohol 
services, homeless services, and the Probation Service. 
Results
The women answered questions on ACEs, with the majority 
having experienced high rates of ACE when compared with the 
general population. The women interviewed were frequently 
affected by nearly all forms of childhood trauma and to a 
far more significant degree than the general population. For 
example, these women were seven times more likely to have 
grown up in a household where there was a family member 
incarcerated and 3.6 times more likely to have grown up in a 
household where there was domestic violence. Overall, these 
women were 10 times less likely to have no ACE at all, when 
compared with the general population. 
The findings were then examined in relation to the needs of 
these women. Particular themes emerged from the interviews, 
where women expressed concerns about a range of issues. 
These included concerns over parenting, such as the fear of 
losing custody of their children, which resulted in a reduced 
Resilience in the face of trauma  
continued
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comprehensive and of great value. However, a recurring issue 
for family members was the financial barrier to treatment.
Staff responses to the interviews/surveys indicated that 
perhaps they were undervalued as part of the wider 
organisation. They also felt that the administration elements are 
particularly time-consuming and therefore impacted on their 
clinical time. Staff felt that the Tabor Group has a particularly 
good reputation; however, they had concerns that the three 
components of the Tabor Group are seen as separate services, 
rather than a collective organisation. 
Recommendations
As a result of the external evaluation, particular issues/areas 
have been identified. A number of recommendations have been 
suggested for consideration, particularly in the following areas:
• Strategic management and governance: Some of these 
issues include the advice that the board should provide 
leadership for the direction of the organisation. The senior 
management team could be restructured to improve 
equality between the three groups. There is a need to 
improve the communication that financial assistance is 
available through the Health Service Executive, as well as 
developing a communication strategy.
• Staffing issues: The findings of the evaluation report should 
be communicated to staff in a series of meetings to discuss 
results. Staff members should have a review of their training 
needs and the clinical director should follow up that annual 
staff appraisals are conducted. 
• Programme issues: As a number of clients raised concerns 
about the confrontational counselling practice, known 
as the ‘hot seat’, and that research has shown that it is 
associated with a higher dropout and relapse rate, this 
practice should be discontinued. The 28-day limit for 
Tabor Lodge should be reviewed on a case-by-case basis, 
to extend this limit where needed. Trauma-informed 
care could also be incorporated into the core treatment 
model. Also, a seamless progression from primary care to 
secondary care needs to be developed in order to become 
the norm. 
Helen Kennelly
1 Ivers J-H and Barry J (2018) An evaluation of Tabor Group. Cork: 
Tabor Group. https://www.drugsandalcohol.ie/30084/
Tabor Group addiction services  
continued
Results
Desk-based analysis results
The results of the desk analysis were compiled from annual 
reports from 2013 to 2017 and were intended to demonstrate 
the similarities and differences between the three services 
in the Tabor Group. Treatment figures were also examined in 
comparison with national and European treatment numbers. 
Trends in demographics, referrals, service utilisation, and 
presentation of complex needs across the three services were 
compiled to examine similarities and differences between the 
three different services. 
Qualitative results 
The qualitative results combined both the results from the 
individual interviews and the focus groups. The qualitative 
analysis asked three questions across a range of service users, 
family members, and staff/board members. These questions 
were:
• What works?
• What does not work?
• What changes would you like to see happen within Tabor 
Group?
The responses to these questions were quite varied, as they 
were taken from significantly different viewpoints; however, 
certain themes and responses repeatedly emerged. 
Service users were mostly satisfied with their interaction 
with the Tabor Group services, noting that the aftercare 
provided was good. However, there was a mixed response 
when asked about the model of treatment, often stating that 
it was very confrontational. The majority also felt that the 
28-day treatment programme was not long enough. Another 
issue identified was a break in the continuum of care from the 
residential unit to the other two services. Clients felt that this 
was a vulnerable period in the treatment and not helpful.
Family members were extremely satisfied with the support 
services provided, stating that the services provided were 
Barriers and enablers 
to HCV screening and 
treatment in Irish 
prisons
Hepatitis C infection (HCV) is a major global epidemic with an 
estimated 399,000 people dying annually from HCV-related 
liver failure and cancer.1 Unsafe injecting drug use is the main 
route of HCV transmission in developed countries, with an 
estimated 20 million people who inject drugs (PWID) infected 
worldwide.2 Over one-half of Irish prisoners report a history 
of opiate use, with 43% reporting a history of injecting.3 A 
2000 study estimated the prevalence of HCV infection in the 
Irish prison population at 37%, increasing to 81% in those 
with a history of injecting drug use.4 With recent advances 
in treatment regimes, HCV is now a curable and preventable 
disease and prisons provide an ideal opportunity to engage this 
hard-to-reach population. However, despite increased access 
to primary healthcare while in prison, many HCV-infected 
prisoners do not engage with screening or treatment.
A recent Irish study aimed to identify barriers and enablers to 
HCV screening and treatment in Irish prisons.5 In this research, 
published in the BMC Harm Reduction Journal, four focus 
groups took place in Mountjoy Prison for males and in the 
Dóchas Centre medium-security prison for adult females at 
the Mountjoy Campus in Dublin. Participants were recruited at 
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both sites by open invitation through posters and directly by 
custodial and healthcare staff. Focus groups were facilitated 
by an experienced team of facilitators and included a series of 
open-ended questions covering the following areas: experience 
of community-based and prison-based HCV screening 
and treatment; barriers and enablers to uptake; challenges 
related to incarceration and release; inter-prison variations in 
healthcare delivery; and the role of security staff and peers in 
prison HCV management.
Results
The following themes related to barriers and enablers to both 
HCV screening and treatment emerged.
Barriers
Lack of knowledge
All focus groups identified lack of knowledge as a major block 
to engagement with HCV treatment services. Prisoners were 
aware of their own lack of knowledge and were often confused 
about the different types of hepatitis. In addition, many 
prisoners were confused about the mode of transmission.
Fear of liver biopsy and treatment and concerns regarding 
confidentiality
Many prisoners spoke about their fear of treatment and the 
negative stories they had heard from other inmates. In addition, 
prisoners expressed concerns regarding confidentiality, with 
some believing that non-medical staff had access to their 
medical records. Many explained how prisoners were often 
called on the prison landing for certain blood tests and hospital 
appointments and that this revealed their medical status to the 
other prisoners and security staff.
Fear of being stigmatised and systematic barriers
In addition to concerns about confidentiality, prisoners 
indicated that there was a fear of being stigmatised by other 
prisoners and staff if they became aware of their HCV status. 
Several participants described a double stigma: the first 
associated with HCV status, and the second being a prisoner 
in a hospital setting. In particular, the practice of handcuffing 
male prisoners for security reasons while attending outpatient 
appointments was identified as increasing the chances of 
experiencing stigma and shame. Many prisoners also expressed 
frustration at the many systemic blocks to screening and 
treatment. These included delays in having bloods taken in 
addition to further long delays in receiving results.
Enablers
Opt-out screening at committal and in-reach hepatology and 
fibroscanning
Screening on committal was seen by most inmates as an 
enabler to treatment, describing it as ‘more private’ and 
‘more suitable’. However, some participants were concerned 
that adapting to new surroundings on committal was already 
a stressful time – with some inmates also having to manage 
withdrawals. Participants identified the presence of in-reach 
hepatology services at both locations as a facilitator to 
engagement with treatment, given that the availability of on-site 
specialist hepatology reduced the need for prisoners to attend 
hospital outpatients. In addition, the majority of prisoners 
expressed satisfaction with access to, and the experience of, 
fibroscanning – with many highlighting that they had better 
access to fibroscanning within prison than in the community.
Stability of prison life and peer support
All focus group participants agreed that prison eliminated many 
of the blocks experienced by this cohort in the community, in 
particular with regard to homelessness, personal motivation, 
competing priorities, and access to healthcare and drug 
treatment. Moreover, participants identified peer educators 
as a potential facilitator to HCV screening and treatment, 
as a number of prisoners had experienced mass HIV and TB 
screening programmes involving Red Cross peer workers while 
serving previous sentences and described it as facilitating their 
engagement. 
Conclusions
The authors noted that although Irish prisons are a key setting 
to identify and treat HCV-infected PWID, this can only be 
achieved by the elimination of identified barriers to HCV 
screening and treatment in Irish prisons. It is hoped that the 
barriers and enablers to HCV screening and treatment reported 
by Irish prisoners in this research will inform both national and 
international public health HCV elimination strategies. 
Seán Millar
1 World Health Organization (WHO) (2017) Global hepatitis report, 
2017. Geneva: WHO. https://www.drugsandalcohol.ie/27177/   
2 Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais DC, 
Horyniak D, et al. (2011) Global epidemiology of hepatitis B and 
hepatitis C in people who inject drugs: results of systematic 
reviews. Lancet, 378(9791): 571–83.     
https://www.drugsandalcohol.ie/15845/ 
3 Drummond A, Codd M, Donnelly N, McCausland D, Mehegan J, 
Daly L, et al. (2014) Study on the prevalence of drug use, including 
intravenous drug use, and blood-borne viruses among the Irish 
prisoner population. Dublin: National Advisory Committee on 
Drugs and Alcohol (NACDA).     
https://www.drugsandalcohol.ie/21750/ 
4 Allwright S, Bradley F, Long J, Barry J, Thornton L and Parry JV 
(2000) Prevalence of antibodies to hepatitis B, hepatitis C, and 
HIV and risk factors in Irish prisoners: results of a national cross 
sectional survey. Br Med J, 321(7253): 78–82.    
https://www.drugsandalcohol.ie/6741/ 
5 Crowley D, Van Hout MC, Lambert JS, Kelly E, Murphy C and Cullen 
W (2018) Barriers and facilitators to hepatitis C (HCV) screening 
and treatment – a description of prisoners’ perspective. Harm 
Reduct J, 15: 62. https://www.drugsandalcohol.ie/30075/ 
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Drug Rehabilitation Scheme – Riverbank Centre, Dublin
As part of their Community Employment Scheme, MQI provides 
a stabilisation programme which seeks to establish a regular 
pattern of discipline and daily attendance in order to help 
clients stabilise and reduce their drug use and prepare them 
for mainstream training and employment. In 2017, some 26 
individuals participated in the programme; most were aged 
between 18 and 39 years of age. Links with the Education and 
Training Boards facilitate the accredited educational component 
for this programme, which helps people gain momentum into 
education and employment.
Family Support Group
MQI offers one-to-one advice and support to family members 
on the realities of drug use and how they can best cope and 
provide optimum support to drug users. MQI also runs a Family 
Support Group (FSG), which meets every week and provides a 
forum where parents, as well as other close relatives and friends 
of drug users, are offered support and advice on a range of 
issues. Participants provide support for each other, and the 
group is continually open to new members. The weekly FSG is 
linked to the National Family Support Network, which offers an 
opportunity to raise issues at a national level. MQI’s FSG in Dublin 
worked with over 40 individuals throughout 2017.
Midlands services
Drug and Alcohol Treatment Supports Project
The MQI’s Drug and Alcohol Treatment Supports (DATS) team 
provides a community-based drug and alcohol treatment 
support service for individuals over 18 years of age and their 
families in the Midlands area (Counties Longford, Westmeath, 
Laois and Offaly). Each county has a dedicated drug and alcohol 
worker to coordinate the care of individuals and families 
experiencing problems due to drug and/or alcohol use. In 2017, 
the team based in the Midlands provided support to 460 people, 
with a total of 4,906 interventions carried out.
Drug Rehabilitation Scheme – Athlone
Supported by Athlone Community Taskforce; the Adult 
Education Centre; the Probation Service; Longford and 
Westmeath Education and Training Board; and South Westmeath 
Employment, Education and Training Services, this programme 
allows clients to participate in activities and educational 
qualifications at an appropriate level on the National Framework 
of Qualifications. The scheme also provided individuals with 
addiction and other rehabilitation supports, for example, crisis 
intervention supports, group work, and key working. In 2017, 
some 22 participants were engaged on this programme.
Rehab and detox treatment services
St Francis Farm Rehabilitation Programme and Detox 
Services
The St Francis Farm (SFF) Rehabilitation Service offers a 13-bed 
therapeutic facility with a 14-week rehabilitation programme 
set on a working farm in Co. Carlow. At SFF, MQI provides a safe 
environment where service users can explore the reasons for 
their drug use, adjust to life without drugs, learn effective coping 
mechanisms, and make positive choices about their future. 
There were 52 clients admitted to the SFF Rehabilitation Service 
during 2017, of whom 27 completed the programme.
The 10-bed residential detoxification service at SFF delivers 
methadone and combined methadone/benzodiazepine detoxes 
for both men and women. The detox activity programme 
includes individual care planning, therapeutic group work, 
Merchants Quay 
Ireland annual review, 
2017
Merchants Quay Ireland (MQI) is a national voluntary agency 
providing services for homeless people and drug users. There 
are 22 MQI locations in 12 counties in the Republic of Ireland (see 
Figure 1). In September 2018, MQI published its annual review for 
2017.1 MQI aims to offer accessible, high-quality and effective 
services to people dealing with homelessness and addiction in 
order to meet their complex needs in a non-judgmental and 
compassionate way. This article highlights services provided by 
MQI to drug users in Ireland in 2017.
Drug services
Health Promotion Unit 
This unit provides drug users with information about the risks 
associated with drug use and the means to minimize such 
risks. MQI offers drug users a pathway into treatment and the 
possibility of living a life without drugs. The main focus is on 
reducing the harms associated with injecting drug use; fostering 
the motivation to become abstinent; and giving advice on HIV, 
hepatitis B virus and hepatitis C virus infection prevention. In 
2017, some 2,583 individuals used the service (an increase of 3% 
on 2016), of which 443 were new clients.
As part of the MQI health promotion remit, a total of 2,691 safer 
injecting workshops were undertaken with injecting drug users 
in 2017, an increase of 26% on 2016. There were 25,358 needle 
exchange visits, an increase of 3% on 2016.
Naloxone provision
Along with partners in the Health Service Executive, the National 
Family Support Network and the Ana Liffey Drug Project, MQI 
was front and centre in the national rollout of the Naloxone 
Demonstration Project in 2015. Naloxone is an antidote for opioid 
overdose that reverses the depressant effects of opiates such as 
heroin. To date, more than 400 drug users have been prescribed 
naloxone, and an external evaluation concluded that the scheme 
was a success. Work on this initiative is ongoing and MQI hopes 
that eventually all opiate drug users in Ireland will have access to 
this life-saving drug.
Community benzodiazepine detoxification
In response to a need identified in 2017, MQI undertook 
to facilitate community benzodiazepine detoxifications in 
collaboration with Granby MQI GP Services. A total of 45 clients 
accessed this programme in 2017. MQI notes that many of these 
clients have since moved on to become drug-free, have gained 
employment, and/or have accessed education programmes in 
addition to accessing residential rehabilitation programmes. 
Community Engagement Team
The Community Engagement Team works to cultivate and 
strengthen relationships between MQI and the local community. 
The team picks up and safely disposes of drug-related litter as 
well as offering some of the most vulnerable people (who are 
rough sleeping or reluctant to engage with services) street-based 
advice and referral into the services they need. A total of 11,951 
items of drug-related litter were disposed of by this team in 2017.
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2007–2017. It also shows the diagnosis of these women. 
During 2017, some 123 women booked into the DOVE Clinic for 
antenatal care. Of these:
• 26 (21%) women were positive for HIV infection. 
• 49 (40%) women were positive for hepatitis B (HBV) surface 
antigen.
• 36 (29%) women were positive for hepatitis C (HCV) 
antibody. 
• 16 (13%) women had positive treponemal serology (syphilis).
It should be noted that these numbers refer to patients who 
booked for care during 2017. Table 1 summarises the outcome 
of patients who actually delivered during 2017. Of these 
patients, 23 were HIV-positive, 49 were HBV-positive, and 38 
were HCV-positive. During 2017, 100 women were referred to 
the Drug Liaison Midwife (DLM) service, including 56 women 
DOVE Clinic, Rotunda 
Maternity Hospital 
annual report, 2017
The DOVE Clinic in the Rotunda Hospital, Dublin was 
established to meet the specific needs of pregnant women 
who have, or are at risk of, blood-borne or sexually transmitted 
bacterial or viral infections in pregnancy. Exposure may also 
occur through illicit drug use. Figures from the clinic for 2017 
were published in the hospital’s annual report in 2018.1 
Figure 1 shows the number of women who booked into the 
DOVE Clinic for antenatal care each year during the period 
1  Dublin
2  Shelton Abbey, Co. Wicklow  
3  St Francis Farm, Co. Carlow 
4  Cork Prison 
5  Limerick Prison 
6  Co. Offaly 
7  Co. Westmeath 
8  Portlaoise, Co. Laois 
9  Co. Longford 
10  Castlerea Prison, Co. Roscommon  
11  Loughran House, Co. Cavan 
12  Leixlip, Co. Kildare
Source: MQI annual review, 2017
Figure 1: MQI locations in Ireland
psychoeducational workshops, fitness training, and farm-work 
activities. There were 65 clients admitted for detox service 
during 2017, of whom 56 completed the programme.
Prison-based services
Addiction Counselling Service and Mountjoy Drug 
Treatment Programme
MQI, in partnership with the Irish Prison Service, delivers a 
national prison-based Addiction Counselling Service (ACS) 
aimed at prisoners with drug and alcohol problems. This service 
provides structured assessments, one-to-one counselling, 
therapeutic group work, and multidisciplinary care, in addition 
to release-planning interventions with clearly defined treatment 
plans and goals. Services offered include: 
• Brief interventions
• Motivational interviewing and motivational enhancement 
therapy
• A 12-step facilitation programme
• Relapse prevention and overdose reduction
• Cognitive behavioural therapy 
• Harm reduction approaches
• Individual care planning and release planning.
In 2017, some 2,547 prisoners accessed the ACS and the MQI 
team delivered 10,252 one-to-one counselling sessions. The 
MQI ACS also coordinated and contributed to the delivery of a 
structured, multiagency eight-week Detox and Drug Treatment 
Programme (DTP) in the Mountjoy Prison Medical Unit. During 
2017, the DTP assisted 44 prisoners in detoxing from methadone 
and benzodiazepines.
Seán Millar 
1 Merchants Quay Ireland (2018) Merchants Quay Ireland: Homeless & 
Drugs Services: annual review 2017. Dublin: MQI.   
https://www.drugsandalcohol.ie/29674/
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Seán Millar
1 Rotunda Hospital (2018) The Rotunda Hospital, Dublin annual 
report 2017. Dublin: Rotunda Hospital.    
https://www.drugsandalcohol.ie/30085/ 
Table 1: Deliveries to mothers attending the DOVE Clinic who were positive for HIV, HBV, HCV or syphilis, or who were attending the drug 
liaison midwife, 2017
Mother’s status HIV-positive HBV-positive HCV-positive Syphilis-positive DLM
Total mothers delivered 23 49 38 21 62
Total mothers delivered <500 g
(including miscarriage)
2 0 0 0 0
Total mothers delivered >500 g 21 49 38 21 62
Live infants 21 49 39** 21 61
Miscarriage 2 0 0 0 0
Stillbirth 0 0 0 1 1
Infants <37 weeks’ gestation 3 0 7 3 12
Infants ≥37 weeks’ gestation 18 49 32 18 50
Caesarean section 8 15 14 11 15
HIV, HBV, HCV or syphilis-
positive infants
0 0* 0* 0 –
Maternal median age 33 31 33 33 –
Source: Rotunda Hospital, 2018
* Final serology test not yet available for all infants.
** One set of twins.
DLM = drug liaison midwife.
Figure 1: DOVE Clinic bookings, by year, 2007–2017
Source: Rotunda Hospital, 2018
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who had a history of opiate addiction and were engaged in a 
methadone maintenance programme. There was a total of 62 
deliveries to mothers under the DLM service in 2017.
DOVE Clinic annual report   continued
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Service of 
Commemoration and 
Hope
The National Family Support Network (NFSN)1 is an autonomous 
self-help organisation that provides support to families and 
respects the experiences of families affected by substance 
misuse in a welcoming non-judgemental atmosphere. On 
Friday, 1 February 2019, the NFSN held its 20th Annual 
Service of Commemoration and Hope. This spiritual, 
multidenominational service is held in remembrance of 
loved ones lost to substance misuse and related causes and 
to publicly support and offer hope to families living with the 
devastation that substance misuse causes. The service was 
preceded by a procession from the ‘Home’ memorial on Sean 
MacDermott Street, Dublin, to the nearby Church of Our Lady 
of Lourdes, led by the band of An Garda Síochána. 
Those in attendance included Ms Catherine Byrne TD, Minister 
of State at the Department of Health with responsibility for 
Health Promotion and the National Drugs Strategy; Comdt 
Caroline Burke, aide-de-camp to An Taoiseach; representatives 
from An Garda Síochána, including Chief Supt Sean Ward and 
Det Supt Brian Woods; Archbishop Diarmuid Martin, Bishop 
Eamonn Walsh and other religious representatives; as well 
as family members, friends, and many people involved in 
substance misuse work. Music was provided by soprano Nickola 
Hendy, Cathal Holland and the Gardiner Street Gospel Choir.
Work of NFSN
In her address to the gathering, Sadie Grace, coordinator of 
the NFSN, spoke directly to family members, stressing that 
they are not alone in their grief. Data from the National Drug-
Related Deaths Index (NDRDI) show that over 700 people 
die directly or indirectly due to drug use on an annual basis. 
She highlighted the NFSN’s many achievements, including 
advocating strongly for accurate figures on drug-related deaths, 
which had culminated in the establishment of the NDRDI in 
2005. The NFSN had also advocated for the rollout of the 
naloxone programme, which was set up to help reverse the 
effects of opiate overdose through training, in recognition and 
response to overdose due to opiates, in addition to appropriate 
administration of naloxone. 
She acknowledged the assistance given by Archbishop Martin in 
helping the NFSN support families financially with funeral costs. 
Sadie highlighted the impact that drug-related deaths can have, 
especially the stigma and shame felt by families, and the need 
for specific bereavement support. This need was supported 
by research carried out by Dr Sharon Lambert, whose findings 
showed that drug-related deaths must be classified as special 
deaths that require specific bereavement support. The NFSN 
advocated for the inclusion of an action in the current drugs 
strategy for provision of bereavement support, specifically for 
drug-related deaths. The first addiction-specific bereavement 
support counselling was set up in September 2018 by the 
NFSN in Dublin’s north inner city, but needs to be available 
nationwide.
Sadie stressed that respite was a crucial lifeline for families 
and, on a positive note, announced that the NFSN has secured 
funding for their annual respite conference.
In relation to drug-related intimidation, she said that 
‘meaningful action’ needed to be taken and that drug-related 
intimidation is affecting families all over Ireland. Sadie finished 
by offering families hope. She stressed that the work of the 
NFSN will continue to advocate for better services for families 
and that their loved ones need person-centred, accessible and 
early intervention. The NFSN will continue to fight for family 
support to be accessible throughout Ireland. She invited any 
family member affected by a drug-related death to contact the 
NFSN for help with their bereavement.
Impact of drug-related deaths
In her address, Minister Byrne emphasised the ongoing valuable 
work of the NFSN. She acknowledged and extended her 
sympathy to the bereaved families present. In addition, she 
stressed her commitment as Minister of State to continue to 
highlight the impact of drug-related deaths and welcomed the 
health-led approach and actions on family support included in 
the new strategy.2 
Dr Sharon Lambert called for a public campaign to help 
decrease the stigma related to drug and alcohol addiction. 
Highlighting findings from her bereavement report, she 
stated that the stigma linked to drug-related deaths leads 
to complicated bereavement. A drug-related death must 
be treated as a special death that requires specialised 
bereavement support and if not provided it can leave a legacy 
of trauma for generations. She also stressed the need for 
treatment services to include family members in addiction 
treatment, as people accessing treatment are too unwell to 
assess and engage in their treatment on their own.
In his address, Archbishop Martin spoke of the lack of respect 
for life within the drug trade with too many young lives lost to 
drugs. He acknowledged the support that women provide to 
other women in their grief and the ongoing support given by 
the NFSN.
For many families, this service was the first time that they 
could openly grieve for loved ones lost to drug use and related 
causes. The volume of family support groups was evident, 
with over 70 support groups from across the island of Ireland 
represented at this year’s service, a stark reminder that drug-
related deaths affect families throughout the whole of Ireland. 
The NFSN runs a 10-week bereavement programme twice a 
year and family members can contact the NFSN and avail of 
assistance from this group. 
Ena Lynn
1 The National Family Support Network can be contacted at 5 
Gardiner Row, Dublin 1 on 01 898 0148 or info@fsn.ie or online 
http://www.fsn.ie 
2 Department of Health (2017) Reducing harm, supporting recovery: 
a health-led response to drug and alcohol use in Ireland 2017-
2025. Dublin: Department of Health.    
https://www.drugsandalcohol.ie/27603/
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Recent publications
POLICY
Support for evidence-based alcohol policy in Ireland: results 
from the Community Action on Alcohol Pilot Project
Davoren MP, Lane D, Kirby J, Gibney K, Kinsley G, Hope A, et al. 
(2019) Journal of Public Health Policy, 40(1): 76–90.
https://www.drugsandalcohol.ie/29899/ 
The aim of this research was to examine the level of support 
for evidence-based alcohol control policy among the Irish 
population. 
The majority of individuals (>50%) supported alcohol policy 
measures. These individuals are more likely to be low-risk 
drinkers, older individuals, and report alcohol-related issues 
in their local area. In the context of Ireland’s Public Health 
(Alcohol) Bill, this research signals support for evidence-based 
strategies including minimum unit pricing and a reduction and 
separation of alcohol sales outlets.
RESPONSES
Resilience in the face of trauma: implications for service 
delivery
Dermody A, Gardner C, Davis S, Lambert S, Dermody J and Fein 
M (2018) Irish Probation Journal, 15: 161–78.   
https://www.drugsandalcohol.ie/30005/ 
This research was commissioned to facilitate a better 
understanding of the women’s needs [presenting to homeless, 
probation and drug treatment services in Limerick city], with 
a view to enabling services to be more responsive. This paper 
presents a brief literature review of trauma and trauma-
informed care, outlines the research findings and makes 
recommendations for future service design and delivery.
How suicide-bereaved family members experience the 
inquest process: a qualitative study using thematic analysis
Spillane A, Matvienko-Sikar K, Larkin C, Corcoran P and 
Arensman E (2019) International Journal of Qualitative Studies 
on Health and Well-being, 14, (1).   
https://www.drugsandalcohol.ie/30204/ 
The current study aimed to explore how suicide-bereaved 
family members (n=8) experienced the inquest process, through 
qualitative semi-structured interviews.
Key recommendations include informing family members of the 
main aspects and purpose of the inquest process beforehand, 
adapting the process to maximise the privacy and comfort of 
the bereaved relatives, and restricting graphic evidence being 
heard, where possible, to minimise distress experienced by 
family members.
Smoking cessation support and obstetric outcomes in an 
Irish maternity hospital
McDonnell BP, Keogan S, Clancy L and Regan C (2019) European 
Journal of Obstetrics, Gynecology, and Reproductive Biology, 
232: 1–4. 
https://www.drugsandalcohol.ie/30003/ 
Although recommendations exist for the management of 
pregnant smokers, information on the antenatal care of Irish 
smokers in pregnancy has not been described. We reviewed the 
care given to smokers in a large urban maternity hospital.
Maternal cigarette smoking appears to be a largely tolerated 
risk factor in the population studied, despite being associated 
with poor obstetric outcomes. We identified an absence of 
smoking cessation services and a lack of intervention and 
structure around care pathways.
Prospective study of provided smoking cessation care in an 
inpatient psychiatric setting
Burns A, Lucey JV, Strawbridge J, Clancy L and Doyle F (2018) 
Journal of Psychosomatic Research, 11: 524–31.   
https://www.drugsandalcohol.ie/29874/ 
This study aimed to evaluate current levels of cessation care 
provided, and 3-month quit-rates, in one such setting in 
Ireland.
Despite a high current smoking prevalence among psychiatric 
inpatients, and similar motivation and quit rates to other 
populations, current cessation care rates are low. Smoking 
cessation care needs to be prioritised in psychiatric settings.
National Drugs Library
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19 Twenty years of the methadone treatment protocol in 
Ireland: reflections on the role of general practice
Delargy I, Crowley D and Van Hout MC (2019) Harm Reduction 
Journal, 16(1): 5. 
https://www.drugsandalcohol.ie/30173/ 
Twenty years of the MTP [methadone treatment protocol] has 
been the mainstay of harm reduction services in Ireland. It 
has provided a network of specially trained GPs who provide 
methadone to over 10,000 patients across Ireland within 
a structured framework of training, quality assurance and 
remuneration. With the ongoing commitment of Irish specialists 
in the field of addiction medicine, further improvements to 
support and treat patients can be made.
Rates of reported codeine-related poisonings and codeine 
prescribing following new national guidance in Ireland
Kennedy C, Duggan E, Bennett K and Williams DJ (2019) 
Pharmacoepidemiology and Drug Safety, 28:(1): 106–11.  
https://www.drugsandalcohol.ie/30150/ 
The aims of this study were to examine a national database 
to assess codeine poisonings before and after the new 
guidance for pharmacists while also evaluating rates of codeine 
prescriptions following the introduction of restrictions on 
supply.
New guidance on codeine supply coincided with an initial 
reduction in reported codeine poisoning cases. This reduction 
was in keeping with the previous trend. However, this was 
without an increase in the prevailing rate of prescription claims 
for these products or potential substitutes. Policymakers may 
consider further restriction of codeine products to improve 
public health outcomes.
Profiling frequent attenders at an inner city emergency 
department
Uí Bhroin S, Kinahan J and Murphy A (2019) Irish Journal of 
Medical Science, Early online.    
https://www.drugsandalcohol.ie/30155/ 
The primary aim was to describe the prevalence of FAs 
[frequent attenders] at an inner city ED [emergency 
department]. A subgroup analysis was undertaken for high 
and very high FAs to establish demographics and other factors 
which might cause them to attend frequently.
This retrospective review is the most detailed assessment of 
Irish FAs undertaken to date. Further studies are required to 
examine the Irish hospitals most at need of Case Management 
Strategy Programmes which we postulate could minimise the 
risk of adverse outcomes for these patients and improve overall 
ED efficiency.
PREVALENCE AND CURRENT SITUATION
A profile of psychiatric in-patient admissions with no fixed 
abode (NFA) 2007–2016
Daly A, Craig S and O’Sullivan E (2019) Irish Medical Journal, 112: 
853. 
https://www.drugsandalcohol.ie/30179/ 
This paper examines admissions for the last ten years for those 
recorded as of no fixed abode (NFA) on the National Psychiatric 
In-Patient Reporting System (NPIRS). 
The paper concludes the need to use routinely collected 
data to help understand and address the need of specific 
homeless sub-groups particularly those on institutional circuits 
that include psychiatric in-patient facilities. To enable this 
it recommends the implementation of the individual health 
identifier as a matter of urgency.
Barriers to progressing through a methadone maintenance 
treatment programme: perspectives of the clients in the 
Mid-West of Ireland’s drug and alcohol services
Moran L, Keenan E and Elmusharaf K (2018) BMC Health 
Services Research, 18(1): 911.     
https://www.drugsandalcohol.ie/30195/ 
To date, very few studies have specifically investigated the 
reasons why a cohort of clients remain ‘trapped’ in the high 
risk, specialist clinical setting. 
To optimise the functioning of the MMTP [Methadone 
Maintenance Treatment Programme], three tasks need to be 
fulfilled: 1) Reduce the incidences of ACEs [adverse childhood 
experiences], 2) Diagnose and treat clients with a dual diagnosis, 
3) Educate clients, their families, the public and allied health 
care professionals on all aspects of OUD [opioid use disorder]. 
A cross-departmental, inter-governmental approach is needed 
to address opioid misuse as a societal issue as a whole.
Five-year standardised mortality ratios in a cohort of 
homeless people in Dublin 
Ivers J-H, Zgaga L, O’Donoghue-Hynes B, Heary A, Gallwey B 
and Barry J (2019) BMJ Open, 9(1): e023010.   
https://www.drugsandalcohol.ie/30198/ 
The aim of this study was to calculate standardised mortality 
ratios (SMRs) for a cohort of homeless people in the Dublin 
region over a 5-year period and to examine leading causes of 
death.
Mortality rates among homeless persons are exceptionally 
high. Services and programmes, particularly housing and those 
targeting overdose and alcoholism, are urgently needed to 
prevent premature mortality in this vulnerable population.
Recent publications continued
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Probation officers’ judgements: a study using personal 
construct theory
Mullineux JC, Taylor BJ and Giles ML (2019) Journal of Social 
Work, 19(1): 41–59. 
https://www.drugsandalcohol.ie/30176/ 
Social workers and probation officers are frequently called 
upon to make judgements about the likelihood of re-offending. 
However, whilst the use of risk assessment instruments is now 
commonplace, the cognitive processes through which these 
judgements are made are rarely explicit.
It is suggested that the design and implementation of 
assessment tools should be undertaken in the light of the 
constructs used in making professional judgements which 
inform the relevant decision making.
Grey matter volume differences associated with extremely 
low levels of cannabis use in adolescence
Orr C, Spechler P, Cao Z, Albaugh M, Chaarani B, Mackey S, et 
al. (2019) Journal of Neuroscience, 39(10): 1817–27.
https://www.drugsandalcohol.ie/30177/ 
In the current study, we used voxel-based morphometry to 
compare grey matter volume (GMV) in 46 fourteen year old 
human adolescents (males and females) with just one or two 
instances of cannabis use and carefully matched THC-naïve 
[delta-9-tetrahydrocannibinol] controls. 
This study presents evidence suggesting structural brain and 
cognitive effects of just one or two instances of cannabis use 
in adolescence. Converging evidence suggests a role for the 
endocannabinoid system in these effects. This research is 
particularly timely as the legal status of cannabis is changing in 
many jurisdictions and the perceived risk by youth associated 
with smoking cannabis has declined in recent years.
Harms from a partner’s drinking: an international study on 
adverse effects and reduced quality of life for women
Callinan S, Rankin G, Room R, Stanesby O, Rao GN, Waleewong 
O, et al. (2018) American Journal of Drug and Alcohol Abuse, 
45(2): 170–78. 
https://www.drugsandalcohol.ie/30127/ 
The aim of this study was to identify the proportion of 
heterosexual intimate partner relationships with a heavy 
drinking male that resulted in reported alcohol-related 
harm and to investigate the impact of this on well-being in 9 
countries.
Harms to women from heavy drinking intimate partners appear 
across a range of subgroups and impact on a wide range of 
women, at least demographically speaking. Women living with a 
heavy drinking spouse experience higher levels of anxiety and 
depression symptoms and lower satisfaction with life.
Recent publications continued
Intention to reduce drinking alcohol and preferred sources 
of support: an international cross-sectional study
Davies EL, Maier LJ, Winstock AR and Ferris JA (2019) Journal of 
Substance Abuse Treatment, 99: 80–87.   
https://www.drugsandalcohol.ie/30183/ 
This paper aimed to assess intentions to reduce drinking and 
the preferred sources of support among a large international 
sample of people who drink alcohol. 
Interest in online interventions for harmful drinking is significant 
and highest among people who drink at low risk. Online tools 
should offer brief screening and feedback, ensuring that people 
with high risk drinking patterns are referred to more specialist 
services.
Method of self-harm and risk of self-harm repetition: 
findings from a national self-harm registry
Cully G, Corcoran P, Leahy D, Griffin E, Dillon C, Cassidy E, et al. 
(2019) Journal of Affective Disorders, 246, 843–50. 
https://www.drugsandalcohol.ie/30170/ 
This study examined risk of hospital presented self-harm 
repetition according to specific characteristics of self-harm 
methods. 
Self-harm method and the associated risk of repetition should 
form a core part of biopsychosocial assessments and should 
inform follow-up care for self-harm patients. The observed 
differences in repetition associated with specific characteristics 
of IDO [intentional drug overdose] underline the importance of 
safety planning and monitoring prescribing for people who have 
engaged in IDO.
An online survey of Irish general practitioner experience of 
and attitude toward managing problem alcohol use
Collins C, Finegan P and O’Riordan M (2018) BMC Family 
Practice, 19(1): 200. 
https://www.drugsandalcohol.ie/30133/ 
This study aimed to explore Irish general practitioners’ (GPs) 
current practice of and attitudes towards the management of 
problem alcohol use.
GPs in this survey reported widespread experience of screening 
and intervention, however, many still felt ineffective. In order to 
maximise the potential impact of GPs, a clearer understanding 
is required of what interventions are effective in different 
scenarios. Furthermore, GPs are only part of the solution 
in terms of addressing alcohol consumption. The services 
available in the broader health care system and Government 
alcohol related policy needs to further support GPs and 
patients.
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Alcohol industry involvement in policymaking: a 
systematic review
McCambridge J, Mialon M and Hawkins B (2018) Addiction, 
113(9): 1571–84. 
https://www.drugsandalcohol.ie/30180/ 
The aim of this study was to summarize the substantive 
findings of studies of alcohol industry involvement in 
national or supranational policymaking, and to produce a 
new synthesis of current evidence.
Alcohol industry actors are highly strategic, rhetorically 
sophisticated and well organized in influencing national 
policymaking.
Non-steroidal anti-inflammatory drugs use, knowledge, 
and behaviours around their use and misuse in Irish 
collegiate student-athletes
O’Connor S, McCaffrey N, Whyte E, Moran K and Lacey P 
(2018) The Physician and Sportsmedicine, Early online.   
https://www.drugsandalcohol.ie/30014/ 
Non-steroidal anti-inflammatory drugs (NSAIDs) are 
commonly used by athletes to treat injuries but are also 
reportedly misused as performance or recovery aids. 
This study aimed to investigate NSAID use, knowledge, 
and behaviour regarding use and misuse of NSAIDs in Irish 
student-athletes.
Education strategies to improve student-athletes’ 
knowledge of appropriate use and side effects of NSAIDs 
are recommended, particularly for those with high levels of 
stress and athletic identity.
EU anti-smoking graphic warnings on cigarette packets: 
semiotics and the issue of gender under-representation
O Doherty D, Houghton F, McInerney D, Duncan B and 
Houghton D (2018) Irish Journal of Medical Science, Early 
online. 
https://www.drugsandalcohol.ie/30002/ 
Smoking remains the leading cause of preventable 
mortality globally and is responsible for significant 
morbidity. The mandatory introduction of combined 
anti-smoking graphic and text warnings on tobacco 
products within the European Union (EU) therefore has 
been welcomed as an important element of the necessary 
war on tobacco. Emerging evidence suggests that such 
warnings are an effective tool, particularly when combined 
with plain packaging.
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19 Recent publications continued Prevalence of potentially inappropriate prescribing in older 
people in primary care and its association with hospital 
admission: longitudinal study
Pérez T, Moriarty F, Wallace E, McDowell R, Redmond P and 
Fahey T (2018) BMJ, 363: k4524.    
https://www.drugsandalcohol.ie/29966/ 
The aim of this study was to determine whether hospital 
admission is associated with potentially inappropriate 
prescribing among older primary care patients (aged ≥65 years) 
and whether such prescribing was more likely after hospital 
admission than before.
Hospital admission was independently associated with 
potentially inappropriate prescribing. It is important to 
determine how hospital admission may affect appropriateness 
of prescribing for older people and how potential adverse 
consequences of admission can be minimised.
The global burden of disease attributable to alcohol and drug 
use in 195 countries and territories, 1990–2016: a systematic 
analysis for the Global Burden of Disease Study 2016
GBD 2016 Alcohol and Drug Use Collaborators (2018) Lancet 
Psychiatry, 5(12): 987–1012.    
https://www.drugsandalcohol.ie/29880/ 
We aimed to use data from the Global Burden of Diseases, 
Injuries, and Risk Factors Study (GBD) 2016 to calculate 
global and regional estimates of the prevalence of alcohol, 
amphetamine, cannabis, cocaine, and opioid dependence, and 
to estimate global disease burden attributable to alcohol and 
drug use between 1990 and 2016, and for 195 countries and 
territories within 21 regions, and within seven super-regions. We 
also aimed to examine the association between disease burden 
and Socio-demographic Index (SDI) quintiles.
Alcohol and drug use are important contributors to global 
disease burden. Effective interventions should be scaled up to 
prevent and reduce substance use disease burden.
